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Abstract 
 
Assessing the responsiveness of the “Challenge of Living with Cystic Fibrosis” Questionnaire 
to change in clinical condition 
Kiri L. Dyer 
 
Background 
Cystic Fibrosis is a chronic, life shortening genetic disorder requiring a demanding daily treatment 
routine to manage, which intensifies during periods of pulmonary exacerbation.  Parents are most 
often the primary carers of children with CF, and so, are responsible for handling the complex 
demands of the treatment regimen. They are, therefore, are at risk of experiencing caregiver 
burden, which may be exacerbated when their child becomes unwell. 
 
Aim 
To assess the responsiveness of the Challenge of Living with Cystic Fibrosis Questionnaire (CLCF), a 
new tool designed to estimate the time and effort involved in caring for a child with CF, to change in 
a child’s clinical condition, and as a result, its applicability in the clinical setting.  
 
Method  
N=13 parents of children with CF aged ≤13, who were at least one year post diagnosis, completed 
the CLCF during a period of wellness and a period of pulmonary exacerbation.  The number of 
minutes per day undertaking treatment tasks and the average effort expended in treatment tasks 
was compared at the two time points. 
 
Results 
There was a correlation between the within person difference in minutes per day and the within 
person difference in average effort (p=0.024), demonstrating a relationship between the amount of 
time spent in treatment tasks and the effort taken to complete them.  There was a trend for parents  
to spend a greater amount of time on treatments during the period when their child were unwell 
compared to when they were well, with a median within person difference of 53 minutes, but this 
did not reach statistical significance (p=0.07).  There was no difference in the average effort 
expended on treatments between the two time points.    These results should be interpreted with 
caution due to the small sample size. 
 
Conclusions 
This has been a valuable pilot study, demonstrating the ability of the CLCF to collect clinically 
meaningful data, and in part, demonstrated the responsiveness of the CLCF.   The CLCF promises to 
be a useful clinical tool, however, further work is required to definitively establish the clinical 
relevance of the CLCF, and confirm the measure’s validity and reliability.  It has also provided data 
on the amount of time parents in this study population spent on treatment tasks for their child.   
This is of particular importance given the expanding number or treatments available for CF, and the 
time taken for parents to provide these should be considered when making treatment decisions. 
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Chapter One 
Cystic Fibrosis 
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Cystic Fibrosis 
 
 
1.1 Aetiology and Epidemiology of Cystic Fibrosis 
 
Cystic Fibrosis (CF) is a recessively inherited multi-system disorder caused by mutations of the Cystic 
Fibrosis Transmembrane Conductance Regulator (CFTR) gene on chromosome seven (1).  The abnormal 
gene alters sodium and water transport across cell membranes, resulting in viscous secretions, most 
noticeably in the lungs and pancreas, manifested by recurrent chest infections and malabsorption.  
Symptoms experienced by patients, particularly during pulmonary exacerbations, include cough, sputum 
production, dyspnoea, decreased energy levels, decreased appetite and weight loss (2).   
 
CF is the most common fatal hereditary disease in the Caucasian population with an estimated 1 in 25 
people carrying the defective gene.  Across the 27 countries of the European Union (EU), the average 
prevalence is 0.737 per 10,000 (3), this is similar to the 0.797 per 10,000 reported by the United States 
Cystic Fibrosis Patient Registry (4). However, both the prevalence and incidence across EU countries 
varies widely, with Ireland having an incidence of 1 in 1353 births and prevalence of 2.98 per 10,000, 
compared to Finland where the incidence is just 1 in 25000 births and a prevalence of 0.123.  The 
incidence in the UK has been estimated at 1 in 2381 births, with a prevalence of 1.37 per 10,000 (3).   
 
It is important to note that CF is not confined to Caucasians, however, the incidence is significantly lower 
in other racial groups; for example the incidence in the Indian population has been estimated at 
between 1:43,231 and 1: 100,323 (5), and in the Japanese population, even lower at 1:320,000 (6). 
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As mentioned above, CF is the most common fatal hereditary disease in the Caucasian population, and 
in the past, children with CF had a short life expectancy, with almost all dying during childhood.  
However, with the advent of better nutrition in the 1980’s and increased pathophysiological 
understanding, particularly the discovery of the CFTR gene in 1989 (1), and the creation of new 
treatments, life expectancy has increased greatly. Most children born in the UK from 2000 onwards are 
now able to expect to live well into middle age (7) , compared to only 21% of those born between 1965 
and 1967 living to the age of 30.  This is a trend echoed in the United States, where, over a twenty year 
period from 1969 to 1990, life expectancy doubled from 14 to 28 years. This trend continues to the 
present day with improvements evident over the recent ten year period from 1994 to 2004 as 
demonstrated by survival curves published by Dodge et al. in 1997 (figure 1.1) (8) and 2007 (figure 1.2) 
(7). 
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1.2 Pathology of Cystic Fibrosis 
 
 
CF is a genetic disease acquired in an autosomal recessive manner; both parents are unaffected carriers 
of the abnormal gene and both parents must pass on the gene in order for an affected child to be born. 
Children of carriers will have a one in four chance of having CF, a two in four chance of being a carrier 
and a one in four chance of having no abnormal genes as shown in Figure 1.3.  
 
 
 
 
 
 
 
 
 
 
             
 
 
 
 
                              
                                                                                  Affected Child 
 
 
 
Figure 1.3 Punnet square displaying the autosomal recessive transmission of genetic diseases 
 
 
The genetic defect in CF is located on the 7th chromosome.  The gene codes for the CFTR protein; a 
chloride channel situated in the apical membrane of epithelial cells, particularly in the airways, 
pancreatic duct, sweat glands, intestines and reproductive tract.  It is composed of 1480 amino acids and 
contains twelve membrane-spanning regions, two nucleotide-binding folds and a regulatory (“R”) 
domain (9). When the gene is mutated it leads to the creation of a faulty, non-functioning protein, and 
AA A 
A a 
Aa 
a Aa aa 
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as such, few or no chloride channels are present in the apical membrane, occurring instead in the 
cytoplasm or not at all.  
 
At present, more than 1000 mutations of the CF gene have been identified, and these have been 
classified according to their molecular impact: 
 Class I (nonsense) – prevent protein production altogether; 
 Class II (trafficking) – proteins produced fail to successfully enter the apical membrane; 
 Class III (regulatory) – proteins are present within the apical membrane but fail to correctly 
regulate chloride ion movement; 
 Class IV (conductance) – chloride ion movement occurs but at a decreased rate and  
 Class V – allow the transcription of some normal CFTR, and may cause a less severe phenotype. 
 
The most common mutation in the Caucasian population, p.del508, falls into class II and accounts for 
68% of CF alleles (10).  The next most common mutation, occurring in 2.4% of alleles is G542X.  
 
CF is not a homogenous condition, and as such there are a variety of phenotypes reflecting, to some 
degree, the wide number of possible genetic configurations; also impacting on this are a range of gene 
modifiers and the environment.  This ranges from the classic phenotype of obstructive lung disease, 
exocrine pancreatic insufficiency and elevated sweat chloride concentration resulting from 
homozygosity for p.del508 or a combination of p.del508 with one of the less common gene mutations, 
to congenital absence of the vas deferens (CAVD); the vas deferens is the most sensitive organ to 
mutations in the CFTR gene. 
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The absence of a functioning chloride channel in the affected cells results in decreased chloride ion 
permeability, this in turn causes an increase in sodium ion transport into the cell and the influx of water 
into the cell by osmosis.  In the airways, this manifests itself as dehydrated airway surface liquid, and as 
such it becomes viscous and tenacious (11,12,12).  These viscous secretions have the effect of flattening 
the epithelial cell cilia, impairing mucociliary clearance of the secretions (see figure 1.4), one of the lungs 
primary defenses against infection. It has been shown that in unaffected individuals, ciliary action moves 
secretions from the distal to proximal airways at a rate of 3-5mm/min with absorption occurring in the 
larger airways; in individuals with CF the secretions have been seen to move in the opposite direction 
(13,14).  Alterations in the lungs defense system allow for colonisation of otherwise harmless bacteria to 
occur within the secretions, leading to chronic inflammation, scarring and cystic bronchiectasis, and 
finally respiratory failure, a viscous cycle (figure 1.5) demonstrated by Henke and Ratjen (15).  Early 
respiratory tract pathogens include Staphylococcus aureus (S. Aureus), haemophilus influenzae (H. 
influenzae) and Pseudomonas aeruginosa (P. aeruginosa).  
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Figure 1.4 Schematic representation of airway epithelial cells affected by CF, demonstrating the 
movement of ions and water 
 
 
 
 
 
 
 
 
Similar mechanisms occur in the pancreas and vas deferens of males, with the secretions in these organs 
becoming viscous and blocking the respective ducts resulting in irreversible damage.  The damage to the 
exocrine pancreas is manifested as malabsorption of fat and the fat-soluble vitamins leading to failure to 
maintain normal growth for age in terms of both height and weight.  Damage to the pancreas can also 
progress to CF-related diabetes.   Damage to the vas deferens results in infertility in about 98% of males 
with CF.  Female fertility is relatively unaffected, but may be reduced due to malnutrition or thickened 
cervical mucus (10).   
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1.3 Diagnosis and Screening 
 
Traditionally, the majority of CF diagnoses are based upon the presence of one or more typical clinical 
features which characterise the CF phenotype: 
 Chronic sinopulmonary disease manifested by: 
I. Persistent infection with typical CF pathogens 
II. Chronic cough and sputum production 
III. Persistent chest x-ray abnormalities; hyperinflation, bronchiectasis 
IV. Airway obstruction 
V. Nasal polyps 
VI. Digital clubbing 
 Gastrointestinal and nutritional abnormalities including: 
I. Intestinal – meconium ileus, bowel obstruction, rectal prolapsed 
II. Pancreatic – pancreatic insufficiency, recurrent pancreatitis 
III. Hepatic – chronic hepatic disease; cirrhosis 
IV. Nutritional – failure to thrive, hypoproteinaemia & oedema, malabsorption, 
steatorrhoea, fat soluble vitamin deficiency 
 Salt loss syndrome 
 Male urogenital abnormalities. 
 
A diagnosis may also be suspected if there is a family history of CF.  The suspicion is then confirmed if 
there is an elevation of sweat chloride above 60mmol/L as confirmed by a sweat test.  In some 2% of 
cases an atypical phenotype presents with normal or equivocal sweat chloride scores and limited clinical 
features, in this circumstance diagnosis may need to be confirmed via genotyping and/or nasal PD (16).  
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Rosenstein and Cutting have presented diagnostic criteria for classical CF on behalf of the Cystic Fibrosis 
Foundation: 
One or more characteristic phenotypic features 
Or a history of CF in a sibling; 
Or a positive newborn screening test result; 
AND and increased swear chloride concentration by pilocarpine iontophoresus on two or more 
occasions 
Or identification of two CF mutations; 
Or demonstration of abnormal nasal epithelial ion transport (16). 
 
 
Since 2007, CF has been included in the UK’s nationwide newborn screening (NBS) programme, which 
also includes screening for phenylketonuria, congenital hypothyroidism, sickle cell disorders and 
medium-chain acyl-CoA dehydrogenase deficiency (17).  The principle for CF screening is based upon the 
presence of elevated immunoreactive trypsinogen (IRT) in dried blood spots from a heel prick as a result 
of blocked pancreatic ducts in insufficiency, a method pioneered in the 1970’s (18).  Since that time, the 
popularity of NBS for CF has increased, and a survey performed in 2004 showed 26 screening 
programmes across Europe, including two nationwide programmes (19).  Since that time number of NBS 
programmes has been added to, with the addition of Britain and Russia. 
 
A recent consensus statement of European best practice for CF NBS has summarised the benefits and 
potential hazards of NBS, and produced guidance statements on how to best manage the results of NBS.  
The benefits outlined include the correct, early, treatment of pancreatic insufficiency and vitamin 
deficiency, and possible improvements in growth, lung function and survival.  It may also decrease the 
psychological effects of diagnosis on the parents and treatment burden.  The potential hazards include 
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parental anxiety, particularly as a result of a false positive result, the problems of managing inconclusive 
screening results and parental knowledge of the child’s carrier status.  There are also issues surrounding 
lack of screening tests for common mutations in ethnic minorities, resulting in the possibility of 
discrimination.  Potential risk to the child from infection due to early exposure to the medical 
environment also exists.  Finally, there are the set up and running costs of NBS schemes to consider (20). 
 
The protocol for NBS varies from centre to centre, however there is a standard protocol on which these 
are based; this has been presented by Castellani et al (figure 1.7) (20).  
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1.4 Routine Treatment 
 
 
1.4.1 Treatment Aims 
 
Following diagnosis, management of CF addresses the multi-system nature of the disease through a 
multi-disciplinary approach geared towards preventing for as long as possible the complications of 
chronic airway infection and pulmonary failure, malnutrition, liver cirrhosis and diabetes.  As such, a 
great deal of the management is pre-emptive of the problems and “routine” as opposed to reactive, and 
it relies heavily upon patient and family co-operation.  The overall aim of treatment is to extend the 
patients’ life expectancy whilst maintaining a good quality of life and their independence.   
 
 
1.4.2 Treatment of Pulmonary Disease 
 
Airway disease is the major cause of morbidity in CF patients, and in 90-95% is also the cause of death 
(10), and therefore, its management plays a central role.   
 
Airway Clearance Techniques 
The aim of airway clearance techniques (ACT) in CF are to aid in the removal of viscous airway secretions 
which would otherwise impede airway ventilation, cause resistance and act as a breeding ground for 
bacteria.  ACT was first introduced in the 1950’s in the form of postural drainage and percussion (PD&P) 
which is a technique employed to make use of gravity; the patient is placed in a gravity-dependant 
position whilst the chest wall is percussed for 3-5mins followed by a period of directed coughing, for 
each lung area.  This is carried out one to four times daily dependent upon clinical condition (21). This 
technique has a number of setbacks, namely the amount of time required and the need for a second 
person.  Furthermore, the original “head-down” position of PD&P has been replaced by modified 
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positions with no tipping due to findings that the head-down position may cause hypoxic episodes (22) 
and aggravate gastro-oesophageal reflux in infants (23).    
 
As much of the obstructive lung disease in CF is caused by secretions plugging the airways, more recent 
efforts at modifying ACT have made use of increased expiratory flow rates and changes in intra-thoracic 
pressure achieved through various breathing strategies to move the secretions upwards.  These 
methods include forced expiration, active cycle of breathing and autogenic drainage all of which can be 
performed independently; however, active cycle of breathing has the advantage that it can be taught to 
children as young as four years of age (21). 
 
When first introduced ACT had little supportive scientific evidence, the first study not being carried out 
until 1971, however this did show that PD&P significantly increased the volume of sputum expelled in 
comparison with coughing alone (24).  This was further backed up by a study demonstrating significant 
decline in pulmonary function when PD&P was stopped for a three week period, with a recovery to 
baseline with re-commencement (25).  Since these initial studies, meta-analyses have consistently found 
that ACT should remain a fundamental aspect of CF care (26,27)(28).  With regards to the newer forms 
of ACT a recent Cochrane review found no advantage of PD&P over the newer methods in terms of 
respiratory functioning and patients largely preferred the independent techniques. (29). 
 
Antibiotics 
Antibiotics are the mainstay of treatment for controlling the airway infections that are recurrent in CF, 
and are used in both a preventative manner and to treat pulmonary exacerbations.  Preventative oral 
antibiotics against S. Aureus, such as flucloxacillin or a cephalosporin, is common in many CF centres 
although, not universal.  In a Cochrane review, Smyth and Wolter found that children treated with 
preventative antibiotics had less evidence of S. Aureus than those who received as required antibiotics 
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(30).  It is, however, argued that there remains insufficient evidence to support the benefits of the 
prophylaxis (31), particularly given the risks of side effects, drug resistance i.e. methicillin-resistant S. 
Aureus (MRSA) and a suggested association with an increased risk of P. aeruginosa (32).  In addition to 
prophylaxis, if prescribed, patients also have a back-up antibiotic, chosen to cover the main pathogens; 
this is employed if an increase in respiratory symptoms occurs and precedes the more stringent 
measures if a pulmonary exacerbation is confirmed (see next section). 
 
Bronchodilators 
Bronchodilators act to relax bronchial smooth muscle; in CF, bronchial smooth muscle may be 
constricted due to a variety of factors, ranging from concurrent asthma, atopy and inflammation caused 
by infection.  As such wheeze and shortness of breath are relatively common in CF patients, and so it 
may be difficult to determine when a bronchodilator will be of use.  One method to determine this is 
testing bronchodilator responsiveness via spirometry, and it has been suggested that a 15% 
improvement in forced expiratory volume at one second (FEV1) is an indication for their use (10).  They 
have been shown to increase FEV1 in CF patients in the short term, and for those CF patients who 
demonstrate a response to bronchodilators may also provide benefits in the long term (33). 
 
Mucolytic Agents 
The indication for mucolytic treatment in CF is the reduction of mucus in the airways; mucolytics achieve 
this through reducing the viscosity of the secretions, allowing for easier movement through the airways.  
The most commonly used mucolytic is aerosolised recombinant human DNase; it acts by breaking down 
DNA (which is released from degrading neutrophils) in the sputum and is indicated to reduce the 
number of acute exacerbations requiring intravenous (IV) antibiotics (15).  It has been shown to reduce 
the risk of pulmonary exacerbation by 28% when administered once daily for six weeks (34). 
 
 
14 
 
Action 
Research 
1.4.3 Dietary Management 
 
Due to pancreatic insufficiency many patients with CF fail to absorb fat and the fat-soluble vitamins, and 
as a result are at high risk of malnutrition and the complications of vitamin deficiency.  Furthermore 
nutritional status has been shown to impact upon clinical variables such as lung function (35). 
 
Pancreatic Enzyme Replacement 
Malabsorption affects up to 95% of individuals with CF, and this is primarily due to pancreatic 
insufficiency, that is, they have insufficient pancreatic enzymes to break down and digest fats.  This is a 
problem rectified by pancreatic enzyme replacement therapy (PERT); orally administered, enterically-
coated replacement enzymes taken whenever food is ingested.  The aims of PERT are to abolish any 
abdominal symptoms such as steatorrheoa, bloating or pain, and maintain a normal bowel habit and 
growth trajectory (36).  PERT effectiveness may be increased by gastric acid suppression by means of 
proton pump inhibitors (10). 
 
Nutrition 
The underlying pathology of CF is thought to lead to increased energy demands, and this, coupled with 
the effects of pancreatic insufficiency is causative of the ensuing problems of failure to thrive, poor 
weight gain and failure to attain full adult height.  As such, it is advised that CF patients exceed the 
recommended daily allowance for calorie intake by as much as 110-200% (that is the amount 
recommended for healthy individuals of the same age and sex) (35).  This is in stark contrast to the 
approach to nutrition prior to the 1980’s when a low fat, low protein diet was employed in order to 
control steatorrhoea (10).  It is recommended that as far as possible this high intake is achieved through 
diet with the addition of regular snacks etc. however, in those individuals whose growth remains static 
or declines over time, medical interventions may be necessary.  These interventions include calorie 
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supplements in the form of drinks, nasogastric tube feeding, gastrostomy feeding or parenteral 
nutrition.  Most patients will also require vitamin supplements. 
 
1.4.4 Monitoring Treatment Effect 
Each year every child with CF will have a number of routine clinic appointments to assess their general 
health and progress, however, in addition to this; every child also has an annual review.  At this annual 
review, the child is reviewed by every member of the multi-disciplinary team and has a number of tests,  
including a chest X-ray and  routine blood tests are performed.  At the end of the review, these 
assessments and test results can be summarised as the Schwachman score.  The Schwachman score is 
an internationally recognised score of clinical severity.  It is scored out of 100, with up to 25 points being 
assigned to each of four domains; general activity, physical examination, nutrition, and chest X-ray 
findings.  A higher score indicates better health(37).  (See appendix 1.1) 
 
 
 
1.5 Novel Therapies 
 
 
With the discovery of the CF gene and greater understanding of the pathological processes behind CF 
came the possibilities for new and innovative ideas for the treatment of CF and, with the advent of gene 
therapy, hopes of a cure.  At this moment there are more clinical trials running for new CF treatments 
than at any other time,  displayed by the Cystic Fibrosis Foundation’s Drug Development Pipeline, 
available at www.cff.org (see figure 1.6) (38). 
 
The drug development pipeline displays a “snapshot” of the treatments that were under development 
as of the 1st April 2009, and covers all aspects of CF management, from gene therapy to nutrition.  It also 
shows the stage of development at which each individual therapy is currently up to in the development 
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process.  The pre-clinical phase refers to treatments which are still at the in vitro and animal testing 
stage, phase I trials involve the testing of the drug on healthy human participants for drug safety, whilst 
phase II and III look at drug efficacy as well as safety in larger groups of the target population.  Phase III 
trials are randomised controlled trials, the gold-standard for assessing interventions. 
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1.6 Pulmonary Exacerbation 
 
Increasingly, patients with CF are ‘well’ on a day to day basis, with few or no respiratory symptoms.  As 
such, the presence of new symptoms may indicate the occurrence of a pulmonary exacerbation; an 
event which has an important impact on the patient’s quality of life (39) as well as their health, and will 
also affect their family and their routine care regime.   
 
As this is an important event, not just in clinical terms for the patient, but also as an end-point for 
research, numerous attempts have been made at establishing a consensus on the diagnostic criteria; the 
most notable being that published by the Cystic Fibrosis Foundation. These criteria were examined in a 
prospective validation and it was found that the following symptoms were the best at discriminating a 
pulmonary exacerbation: 
 Decreased exercise tolerance; 
 Increased cough; 
 Increased sputum; 
 School or work absenteeism; 
 Increased sounds on lung examination and 
 Decreased appetite. 
 
The addition of FEV1 into the criteria was found not to affect sensitivity or specificity, and in paediatric 
populations, is not suitable as many young children are unable to perform spirometry (40).  Despite this, 
there may still exist a lack of agreement within the field, as displayed by Dakin et al in their attempts to 
reach a consensus on criteria for pulmonary exacerbation in 2001 (41).   
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Exacerbations may develop acutely, or over a period of weeks and often reflect increased airway 
obstruction and inflammation.  This may be in response to a new pathogen, or more frequently due to 
precipitation of an existing chronic infection, the most common of which is P. aeruginosa.   Many CF 
patients are infected with this organism by their late teens, and it is known to be associated with an 
increased decline in respiratory function and increased mortality.  Its ability to establish chronic 
infections, despite the use of vigorous antibiotic treatment, lies, in part in the bacteria’s capacity to 
create biofilms on damaged epithelia (42).   
 
Precipitants of pulmonary exacerbations include (43): 
 Non-adherence to routine treatment; 
 Viral infection; 
 Mucus plugging; 
 Fungal infection – bronchopulmonary aspergillosis (ABPA) and 
 Lobar/segmental collapse. 
 
Treatment of exacerbations varies on the basis of the causative organism(s) and its antibiotic 
sensitivities on sputum culture.  Prior to receiving sputum results, choice of antibiotics may be directed 
towards the major pathogens according to previous sensitivity results (10).  It is usual practice to select 
two different antibiotics with different mechanisms of action, most commonly a β-lactam ring and an 
aminoglycoside; they may be administered orally, via nebuliser or via IV.  In the case of P. Aeruginosa 
there is only one class of antibiotics that is active when administered orally – the quinolones; as such 
ciprofloxacin is the most commonly used oral antibiotic for p. Aeruginosa infection.  As this is the only 
oral antibiotic available for this pathogen, if the oral route is chosen for treatment then the second 
antibiotic must be either nebulised colistin or tobramycin (43).  If it is deemed that IV treatment is 
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required then this does not necessarily mean an in-patient stay for the patient, as it is now possible to 
administer IV’s at home, allowing patients to continue attending school or work etc.  The outcomes of 
home IV’s compared to an in-patient stay have been extensively studied and subject to much discussion 
and argument in the literature, and this is still not concluded.  A Cochrane review was only able to 
include one study of seventeen identified studies, and concluded that there was no difference in 
outcome, however the limited evidence base means that this cannot be taken as a given and further 
work is required (44).  Although antibiotics are the mainstay of treatment for exacerbation, other 
therapies such as ACT should not be neglected and should be continued, if not increased.  Extra care 
should also be taken with nutrition during an exacerbation, as the presence of concomitant anorexia can 
cause substantial weight loss over a short period of time.   
 
It is important to bear in mind that during periods of exacerbation, patients and their families may 
spend considerably more time and expend more effort on their treatments than during a period of 
wellness, and that as a result, an already stressful situation (that of being unwell) may be compounded 
by the addition of medications and therapies. 
 
 
 
1.7 Treatment Adherence 
 
 
As previously mentioned, poor adherence to treatment can result in pulmonary exacerbation and a 
decline in respiratory function, increasing both morbidity and mortality and decreasing quality of life. As 
such an understanding of the reasons for low adherence is essential in order to combat it.  Prior to 
beginning a discussion on adherence, it is important to understand the terminology, as the terms 
compliance and adherence are often used interchangeably in the literature; the differentiating factor 
between the two being the role played by the patient in the decision making process: 
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Compliance – “the extent to which patients are obedient and follow the instructions, proscriptions, and 
prescriptions of health care professionals.” 
 
Adherence – “an active, voluntary, collaborative involvement of the patient in a mutually acceptable 
course of behaviour to produce a desired preventative or therapeutic result.” (45)  
 
Poor adherence in chronic illness is commonly documented, with average rates of treatment adherence 
generally lying at less than 50% (45).  In CF the assessment of adherence can be complex due to the 
range of therapies, with adherence rates varying for specific treatments (46) (47), this is further 
complicated by the measurement methods employed by researchers.   
 
The most frequently used method of assessing adherence is patient self-report, due to its ease of 
application and relative inexpense.  This method, however, has been shown to inflate adherence rates 
by as much as 100% when compared to other methods (48), and is prone to both reporting and recall 
bias, meaning that this method used alone is highly unreliable.  Despite this, in a review of adherence 
research it has been found that in 36% of studies examined this was the case (49), casting doubt on the 
evidence base in this subject area.  A method often used in combination with self-report are prescription 
refill histories, whereby pharmacy databases correlate the type and amount of medication dispensed to 
the patients and their refill dates. Although an improvement on self-report alone, it does not confirm 
that the medication is actually taken or in the right way.  An increasingly popular method are daily 
phone diaries; a procedure in which the researcher phones the participant and asks them to recount all 
their activities for the previous twenty-four hours.  Even though this is a self-report approach, it is less 
vulnerable to recall bias due to the short time frame involved, and decreases report bias as it enquires 
about all activities carried out not just those related to adherence behaviour.  Due to the nature of the 
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information collected, this makes it the best way of identifying the underlying causes of poor adherence, 
but it is also its downfall because it is both time-consuming and complex to analyse (48).  The most 
recent development in adherence measurement is the advent of electronic devices such as metered 
dose inhalers, opening pill bottles and nebuliser machines – these devices allow the recording of data 
such as the date, time and duration of treatments in an unbiased manner, and it is possible that they 
become the “gold standard” of adherence research (48). 
 
A recent example of this is a study conducted by McNamara et al monitoring the adherence to nebulised 
antibiotics by children infected with P. Aeruginosa.  Using an adaptive aerosol delivery device with the 
ability to monitor when the device was used, for how long, and whether a full antibiotic dose was taken, 
the authors retrospectively examined the adherence behaviour of 28 patients with P. Aeruginosa over a 
twelve month period.  Adherence data were openly discussed with the patients following collection 
(occurring at routine clinic visits), and in eight patients their treatment regimen was changed in 
response to the data collected in the second six months of the year.  Mean overall adherence during the 
first six months was 67%, and this was maintained at a rate of 60-70% for the remainder of the year.  
The authors identified substantial variation both between and within patients, but of particular interest 
was the finding that adherence was significantly better in the evenings (75%) than the mornings (58% 
p=0.012) (50) – a unique finding, which would have been difficult to demonstrate without the use of 
electronic monitoring, underlining its importance in the progression of adherence research. 
 
A study conducted by Modi et al. has attempted to not only assess the rates of adherence to treatment 
in children with CF, but also to assess the convergence across the different measurement methods 
described above and identify the measure which most strongly correlates with electronic monitoring, 
the ‘gold standard’ (48).   The study examined the adherence behaviour of 37 children aged six to 13 
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with a confirmed diagnosis of CF through the use of the Disease Management Interview-CF as the self-
report measure, prescription refill data from the patient’s pharmacy, a daily phone diary and the 
Medication Event Monitoring System for enzyme medications.  It is important to note that twenty-six of 
the participants were also enrolled in a large adherence intervention trial.   
 
The study found that in accordance with the evidence base, the adherence rates varied both with 
treatment and the kind of measure used. Rates of adherence for ACT were highest, ranging from 64% to 
74% depending on which measure was used. For nebulised medications adherence rates ranged from 
48% (diary) to 82% (parent self-report), adherence for vitamins was also variable with child self report 
giving rates of 94% but diary data only 22%.  This level of variability also existed for enzymes; 27% 
adherence reported with the diary compared with 90% by child self-report.   
 
As well as individual treatment adherence rates, the overall adherence rate was calculated using the 
objective measures and found to be less than 50%,  compared to that of the subjective measure (self-
report) which in both parents and children was approximately 80%.  This clearly demonstrates the 
dangers of relying on self-report data as the main method of assessing adherence rates in the CF 
population, and also demonstrates the variability in adherence to the individual aspects of the CF care 
regimen.  What this study does not address in any way is the factors influencing the adherence rates – 
why were the children in this study more adherent to ACT than to enzyme replacement therapy?   
 
There are a wide variety of factors that have been investigated and are thought to play a part in 
determining levels of adherence.  Of importance in CF, a chronic disease requiring long-term 
management, is the literature suggesting that adherence decreases as the duration and complexity of 
treatment increases (51). Further evidence has also suggested that specific treatment characteristics 
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such as the number of medications, the frequency of dosing, and routes of administration have an 
impact on the degree of adherence (52) (53) – all of these variables will almost certainly be of relevance 
in CF.  Other areas of the literature have suggested that a poor knowledge of a chronic illness and its 
management will be associated with lower levels of treatment adherence (54), but as logical as this 
seems, studies have shown that this is in actual fact, poorly correlated with adherence rates in CF (46) 
(47).    Further correlates with adherence levels may be the degree of worry about the condition and the 
level of trust in medical practitioners (55).  Much of this research has been conducted in adults with CF, 
and indeed, when asked directly why they do not adhere to prescribed treatment regimens, many CF 
adults state forgetfulness (46,47), little has been done in the way of assessing reasons for low adherence 
in paediatric populations. 
 
An exception to this is a study by Modi and Quittner, which analyses the reasons for poor compliance in 
six to 13 year old children with CF and asthma (56).  Thirty-seven children with CF and 36 with asthma 
had their adherence behaviour monitored by means of: 
 Their prescribed treatment plan; 
 The disease management interview-CF; 
 Prescription refill data; 
 Daily phone diary; 
 Electronic monitoring; 
 Barriers to adherence interview and 
 The CF knowledge questionnaire or the asthma questionnaire. 
 
In the CF group, parents and children identified barriers to enzymes, ACT, nutrition and nebulised 
medications; the authors identified that these are some of the most time-consuming treatments (an 
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aspect of adherence behaviour which has not been extensively studied).  The barriers identified for 
these treatments varied between the child and parents.  Parents reported oppositional behaviour, 
forgetting and time management as barriers, whilst children identified problems such as difficulty 
swallowing pills or dislike of the taste of medications.  Also examined was the effect of disease related 
knowledge of both the children and parents; on the whole the parents had a good understanding of CF, 
but a poor knowledge in relation to nutrition, with 92% unaware that fat has more calories than 
carbohydrates; an important factor when coupled with evidence of low adherence to nutritional 
interventions (48).  Differences in the parent’s belief of the prescription and that of the physician were 
also found, with 17% of the parents disagreeing with the medications prescribed; suggesting that poor 
communication between medical professionals and parents may play a role in adherence levels, a 
finding that has been reported elsewhere (57).   
 
This short summary on adherence has covered the practical issues relating to CF and adherence, 
however other features do play a role and should be considered, namely psychological factors such as 
coping mechanisms; for example it has been found that acceptance and hopefulness are more 
conducive to adherence than avoidance or denial strategies (58).  These factors will be covered in 
greater detail in a later section. 
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Chapter Two 
Burden of Care 
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Burden of Care 
 
 
2.1 History of Burden of Care 
 
 
The study of caregiver burden began in the 1960’s in response to the de-instutionalisation of mental 
health patients, and the growing trend to treat patients within their families.  In 1963 Grad & Sainsbury 
(59) were the first to consider how this may impact on the family and particularly those family members 
directly caring for the patient.  This led to the first definition of burden of care in the literature, 
presented in 1966 by Grad and Sainsbury as “any cost (negative consequences) to the family of which 
the patient is a member” (60).  Soon after, Hoenig and Hamilton dichotomised burden into objective and 
subjective dimensions.  In their study of schizophrenic patients discharged to home in the care of family 
members, they classified objective burden as adverse effects on the household (financial loss, effects on 
health of other family members, the effect on children and general disruption) and any type of abnormal 
or disturbing behaviour by the patient.  Subjective burden was described as “what the relatives 
themselves felt about it, and to what extent they considered they had carried any burden” (61).  This 
important distinction between the objective and subjective aspects of burden led the way for 
clarification of the concept by subsequent authors, and later the development of the current view of 
burden as a multi-dimensional construct. 
 
However, despite the early breakthrough by Hoenig and Hamiliton, little work on the area followed until 
the 1980’s, when, in 1980 Zarit et al. produced a new definition of burden; “the extent to which 
caregivers perceived their emotional, physical health, social life and financial status a result of caring for 
their relative” (62).  Importantly, these authors identified that providing care to a relative did not 
directly proceed to unavoidable negative consequences, but that feelings of burden were the result of a 
specific, subjective, interpretive process within the individual caregiver. Thompson and Doll followed 
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this up in 1982, undertaking a study aiming to take the concept a step further than previously, through 
identifying individual factors contributing to subjective burden.  They also examined the relationship 
between subjective and objective burden, sociodemographic status and the psychiatric symptoms of the 
patient (63).  The study delineated subjective burden into five dimensions; embarrassment, overload, 
entrapment, resentment and exclusion.  Furthermore, it was one of the first to show that the presence 
of objective burden did not predict the presence of subjective burden, and vice versa; although there 
was a correlation (tau = 0.26) between objective and subjective burden, they shared just 7% common 
variance (63).  
 
The acknowledgment of the importance of the subjective aspect of burden was carried forward in 
further work (64,65), and is now a fundamental component in the burden of care concept.  Researchers 
continued to attempt to further refine the subjective/objective dichotomy with Platt et al stating 
“Objective burden differs from subjective burden, which depends entirely on caregivers sharing their 
personal feelings (66)”.  However, despite the increasing attention the burden of care concept was 
attracting in the literature, little progress was made in furthering the concept, indeed, questions began 
to arise regarding how useful it truly was, and it was argued that with the increasing research into the 
subject the concept itself was becoming increasingly undefined and vague due to the many definitions 
and concepts put forward by a wide array of authors (67).  In the 1992 critique of the care giving 
literature by Braithwaite, it was pointed out that in order to make the concept scientifically relevant and 
useful there must be some restriction of the definition (67); an attempt at this had in fact been made by 
Poulshock and Deimling in 1984 when they had argued the need to distinguish the impact of caregiving 
(e.g. on social life, employment) from the distress caused by dealing with the dependence of the person 
they cared for (64).  Understandably, this was not entirely accepted, as the model suggested by 
Poulshock and Deimling failed to take into account that distress caused by the impact of caregiving, an 
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issue not missed in Braithwaite’s critique; “it is to justify why distress over time constraints or family 
disharmony would not constitute burden while distress over an elderly person’s memory loss would 
(67).” In her conclusion Braithwaite noted that there were two routes of taking the concept forward, 
that favoured by her; restricting the definition and embedding it within the stress paradigm, and a 
second approach, which would ultimately lead to the current understanding of burden; dissecting it into 
a number of components or dimensions.   
 
It was this second approach, taken by Kosberg et al in the construction of their Cost of Care Index, which 
led the way for burden of care as it is currently understood.  They argued that the measurement of 
overall burden, using only a dichotomy and a global scoring system, leaves a knowledge gap; the ability 
to identify those specific problem areas which affect caregivers, thus rendering the concept pointless – if 
you cannot identify these specific problems how are interventions to be put in place to counteract them 
(68)?     
 
 
 
2.2 Burden of Care: The Concept 
 
 
The burden of care concept can be broken down into four broad areas, namely: 
 its critical attributes - features which are central to the concept; 
 the predisposing factors - factors which increase the risk of a caregiver feeling burdened; 
 the mediating factors - factors which alter the perception of burden and the and 
 consequences – the impact of caregiver burden. 
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2.2.1 Critical Attributes 
 
Subjective Perception 
As described above, subjective perception is central to the burden of care concept and was first 
dichotomised from objective burden by Hoenig and Hamilton in 1966 (61).  Essentially, it means that in 
the same set of circumstances no two caregivers will necessarily interpret and respond to them in the 
same way, and so identifies the fact that the best placed person to identify whether they feel burdened 
is the caregiver themself.   
 
Multi-dimensional 
The multi-dimensional aspect of the concept is concerned with the way in which the impact of chronic 
illness is considered.  Prior to 1977, illness was only considered by the medical profession in terms of the 
disease itself, with little attention paid to the psychological or social issues illness presented to the 
patient.  This viewpoint changed when Engel published his biopsychosocial model, encompassing not 
only the biophysical aspects of illness but also the psychosocial, broadening the way in which the 
medical profession viewed illness (69).  Therefore, when the burden of care concept is described as 
multi-dimensional, it is in this sense – looking not only at the physical impact of caregiving, but also at 
the psychological, social and economic impact. 
 
Dynamic Change 
It is thought that burden is not a static experience; it is believed that as the various components of 
burden fluctuate, so will the level of burden experienced by the caregiver.  It has been suggested that in 
chronic illness, caregivers will eventually “get used to” the circumstances, and their feelings of burden 
will remain stable or subside (70); a stance which has been strongly refuted (71).  It has been recognised 
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in a review of caregiving measures that they are frequently only administered on one occasion (72), and 
as Perlick et al (71) state, a lack of longitudinal data makes it impossible to draw conclusions with 
regards to change over time. 
 
Overload 
Feelings of burden are experienced when the caregivers’ resources are outstripped by the demands 
placed upon them.  These demands can be classified as either primary or secondary, depending on their 
origin, and will be discussed in more detail in a later section.  In a model displaying the relationship 
between caregiver resources and caregiver demands, Romeis shows us that even when care receiver 
demands are high, so long as the caregiver has the necessary resources to deal with those demands 
then caregiver burden will be low.  It is only when the available resources become inadequate that 
feelings of burden result (73).   It is this imbalance, which has been termed overload (74), that is 
necessary for feelings of burden to develop, and so is a critical attribute of the burden concept. 
 
 
2.2.2 Predisposing Factors 
 
 
Gender 
It has consistently been shown that the majority of caregivers are female (75-77), with anywhere 
between 47% and 80% of the caregiver population being made up of women.  Furthermore, in these 
studies the female caregivers perceived themselves to have a greater burden than that described by 
their male counterparts.  It has been hypothesised that men and women experience the caregiving role 
differently due to role socialisation, with men experiencing less stress, instead focusing on specific goals 
and accomplishments (78).     
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Socioeconomic status 
The resources available to a family when coping with the challenges of caregiving can influence the way 
in which the caregiving experience is perceived, and money is an important aspect of this.  The financial 
costs of caregiving are perhaps less relevant within the context of the NHS, than for example in the 
United States where a family may be directly responsible for medical expenses.  Despite this, other 
financial costs still exist, most often in the form of one or more family members changing their role in 
the work place; cutting from full-time to part-time hours or giving up work all together (72).  Studies 
have shown that family income is a primary factor in the ability to access services, such as respite or 
child care, to minimise the impact of burden (79), and it has been found to correlate with the presence 
of burden (75,80).   
 
Income is not the only aspect of socioeconomic status to affect the degree of burden experienced by the 
family.  The level of education achieved by the principal caregivers may also have an impact on the 
presence of burden, principally due to the awareness of, and ability to, access any help available which 
may reduce the demands on the caregiver (72), educational level will also have an impact on the jobs 
accessible to the caregiver, and so relate back to income and financial burden placed on the family. 
 
Furthermore,  families in lower socioeconomic groups have a greater number of “daily hassles” to 
contend with when compared to those in higher social groups, and so the addition of a family member 
requiring care, will only add to these strains, putting those in lower socioeconomic groups at increased 
risk of experiencing caregiver burden (72). 
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Race/Culture 
It is well recognised that family roles and structure vary widely across countries and cultures, and 
attitudes to family caregiving are no different (81).  As communities become increasingly ethnically 
diverse it is important to recognise the impact that race and culture may have on the ways in which 
caregiving is perceived, and it has been demonstrated that race can influence the degree of caregiver 
burden experienced (82).  The affect of culture and race on the caregiving concept is not a simple one 
due to the presence of possible confounding factors such as socioeconomic status, and has been little 
researched, but is should nevertheless be considered. 
 
Caregiver Health 
Caregivers in poor health have consistently been found to be at greater risk of experiencing burden 
thank those in good health (75,83).  This is may be due to the additional tasks associated with taking 
care of their own health, as well as having to take responsibility for the health of another.  Care should 
be taken with this aspect on the burden of care concept as, as well as being a risk factor, care giver 
health is also an outcome, and as Bull points out, the relationship between burden and health can alter 
as the caregiving situation progresses (75).  It is possible that caregiver health and the perceived level of 
burden have a bi-directional relationship. 
 
Psychological Factors 
A number of caregiver psychological factors have been hypothesised to moderate the perception of 
burden; primarily as a means of explaining why some caregivers appear to benefit from the caregiving 
process as opposed to experiencing burden.  The first of these factors is the sense of obligation or 
responsibility experienced towards the person the caregiver is caring for. This may motivate the 
caregiver to stop other activities, such as social engagements or hobbies, due to worry or guilt over 
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leaving the care receiver; these feelings may also decrease their enjoyment of those activities they do 
continue with, thus increasing the amount of perceived burden (74).   
 
A psychological factor hypothesised to decrease burden is the degree of affection and reciprocity 
between the caregiver and care receiver.  It has been suggested that the existence of a past relationship 
between the two parties may complicate or enhance the caregiving process, and may also affect the 
quality of their current relationship.  Furthermore, studies have reported that parents of children who 
describe a good relationship with their ill child perceive lesser degrees of burden (84,85), implying that 
caregiver burden may be decreased when the relationship is characterised by higher degrees of 
affection.   
 
The level of ego-development of the caregiver may also moderate the degree of burden experienced, 
with greater ego-development equipping the caregiver with the ability to better deal with the various 
stressful situations experienced by caregivers.  However, the evidence for this is contradictory (74), and 
requires further investigation.  The final, possible mediating factors, again with limited evidence, are 
personality factors such as locus of control, efficacy and hardiness.  Most work has examined hardiness, 
with studies to suggest that hardiness decreases the effects of stressful life events, such as taking on a 
caregiving role, and increases the use of resources such as social support (86,87).   
  
Demands on the Caregiver 
The demands on the caregiver may be split into primary and secondary demands, a distinction made by 
Pearlin et al in 1990 (88).  Primary demands are those demands placed on the caregiver by the care 
receiver, whilst secondary demands come from other family members, work or the rest of society.   
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A major primary demand experienced by the majority of caregivers is related to the degree of functional 
limitation of the care receiver.  This was first identified in the early stages of burden research conducted 
in mental health, where a relationship between the severity of the patient’s symptoms was related to 
the burden experienced by the family (89,90).  The most common primary demands placed on 
caregivers are those concerned with the activities of daily living (ADLs) and treatment tasks, such as 
giving medication, however, this will vary greatly according to the disease process in question.  For 
example, those caring for relatives with dementia (91), neurological disorders (92) or cancer (93), are 
likely to have very different demands placed upon them than those caring for relatives with more 
chronic conditions such as renal failure or CF, although, this will evolve as the disease process progresses 
(94).   
 
A second important primary demand which has been identified throughout the caregiving literature is 
the presence of behavioural problems; an issue particularly highlighted in the mental health and 
paediatric literature.  Both research areas identify that the need for constant attention and vigilance is a 
potent stressor, which can lead to fatigue and anxiety, and in the dementia patient, a constant reminder 
of how their loved one has changed, adding additional distress (88,95). 
 
As mentioned above, secondary demands also constitute part of caregiver burden, and these demands 
are derived from areas unrelated to the care receiver.  Pearlin et al identified a number of secondary 
stressors, namely, employment, with caregivers also working outside the home experiencing various 
pressures impacting on their caregiving role, economic strain, as discussed above, and social activities, 
which may be severely diminished and missed (88), leaving the caregiver with little opportunity to relax 
and escape the caregiver role.  An additional secondary stressor, identified by Noh and Turner is the 
presence of young children in the household (96).   
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Caregiving Involvement 
Caregiving involvement has been defined as the number of caregiving tasks performed and the amount 
of time it takes to perform them (97).  It has also been suggested that the purpose, or quality, of the 
caregiving task is important to this aspect of the burden of care concept (74). Caregiving involvement is 
an essential component of objective burden as it quantifies the caregiving role, allowing measurable 
comparison both within and between caregivers.  Both the number of tasks (97) undertaken and the 
amount of time taken to complete them have been positively associated with caregiver burden (91).  
Furthermore, as might be expected, it has been demonstrated that the time involved in caregiving tasks 
varies between illness groups (98). 
 
 
 
2.2.3 Mediating Factors 
 
 
Coping Strategies 
The adoption of various coping strategies by family caregivers has been shown to moderate the amount 
of burden felt by the caregiver.  Specific types of coping behaviour appear to have a greater impact than 
others; authors have shown that the employment of social and spiritual support, both from family and 
external sources, (help seeking behaviours), can decrease the degree of burden (99,100).  Those 
previously mentioned are considered to be external coping strategies, in addition to these, three 
internal coping strategies have been found to lower the perceived burden; confidence in problem-
solving, reframing the problem and passivity.  The influence of coping strategies on burden does not 
only be beneficial to the caregiver, it can also be detrimental, as some coping strategies have been 
identified as being maladaptive and worsening burden (101).       
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Social Support 
Social support has long been viewed as one of the primary means by which caregivers alleviate burden 
(102), and has been shown to negatively correlate with perceived burden (75).  The support available is 
characterised by the size of the family network, density, homogeneity of membership, and dispersion of 
membership (72).  Pearlin et al note that as well as the direct impact the availability of social support has 
on the perception of burden, it also acts to decrease the effects of secondary demands (88), and as such, 
its importance, and whether a caregiver is effectively using the available social resources, should always 
be considered.   
 
 
2.2.4 Consequences 
 
 
Caregiver 
Caregivers’ experience a range of negative consequences as a result of their caregiving role, these can 
generally be summarised as those affecting their physical health and those affecting their psychological 
well being.  There are also negative consequences in terms of their ability to maintain a social life, or 
pursue a career, indeed, caregiving has been described as the “caregiver career”, which is often 
unexpected and not part of the caregiver’s life plan (103).  It has been suggested that these restrictions 
on life can place caregivers at risk of social isolation (104)   
 
In terms of physical health, the most common problems are generalised complaints such as chronic 
fatigue, insomnia, weight change etc, and these are well recognised throughout the caregiving literature 
(74), but these are relatively difficult to assess and quantify, and thus compare between groups.  Of 
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greater ease with regard to this, are the psychological outcomes of caregiving, which were summarised 
by Coppel et al in 1985 as: 
 depression; 
 anger; 
 worry; 
 discouragement; 
 guilt and 
 anxiety (105). 
 
Depression, in particular, is somewhat easier to measure and, therefore, compare between caregivers 
and non-caregivers, or between caregiving populations, due to the presence of reliable diagnostic 
criteria and valid self report measures such as the Beck Depression Inventory (BDI) (106).  Indeed, it has 
been shown, that caregivers can report up to three times more depressive symptoms than their 
matched non-caregiving peers (71,92). 
 
Care receiver 
It follows that if burden has a negative impact on the health of the caregiver, then this may in turn, have 
a negative impact on the health of the care receiver; as the caregiver increasingly struggles with the 
responsibilities and demands of providing care they are at risk of becoming less able to provide the care, 
and as such the health of the care receiver may suffer.  This in itself, is a problem; as has been discussed 
above, the health and abilities of the care receiver are a predicting factor of the degree of burden 
experienced, and so, there is a possibility of entering a vicious circle with both the caregiver and care 
receiver’s health progressively declining, unless intervention is made.   Evidence has shown that distress 
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in the caregiver correlates with increased psychological outcomes, such as depression and apathy, in the 
care receiver (107). 
 
Family 
Conflict within families and/or marriages is a major negative consequence of the caregiving role.  
Conflict arises due to the need of the caregiver to fulfil multiple roles within the family, and the strains 
that may be associated with this.  As many as 30 to 56% of caregivers have reported experiencing family 
or marital conflict as a result of their role (74).  Cases of parents separating as a result of caring for a 
chronically ill child have been reported (108). 
 
As well as the impact on marital relations, caregiving can also impact on children within the family, 
whether this is children living in the same house as an adult receiving care, or the sibling of a chronically 
ill child.  In the latter situation, it has been hypothesised that poor maternal well being can have a 
negative consequence on sibling relationships, and therefore the children’s well-being.  The same study 
showed a relationship between the nature of the sibling relationship and maternal well being, with 
mothers of siblings who had aggressive relationships with frequent disagreements, experiencing greater 
distress and burden (109). 
 
In addition to the psychological effects of caregiving on the wider family, are the financial costs 
associated with it.  This issue has been described extensively above, but it is important to clarify that, 
financial difficulties, as well as constituting a predisposing factor of burden, may also be a consequence.  
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2.3 Burden of Care in Paediatrics 
 
 
Burden of care in paediatrics is a unique situation, as parents are caregivers, even if they do not have an 
ill child; in essence, when their child is unwell their role as caregiver is expanded to encompass all those 
issues that come with caring for a person with a chronic illness.  It is unsurprising that the concept of 
burden of care, developed in the adult population, predominantly in dementia and mental health, has 
translated easily to the paediatric population.  This is particularly so in light of Sales’ description of the 
process through which specialties identify caregiver burden as a problem.  She depicts this recognition 
as a number of stages: 
1. An exclusively biomedical focus; 
2. Recognition that the family is a “key medical ally” in providing support to the patient; 
3. Recognition of the problems the family may have in coping with the patient’s illness and 
4. Recognition of the physical and mental health impacts on family caregivers (94). 
 
Given that the second step is almost a prerequisite in the field of paediatrics, and that research into the 
impact on the family of childhood chronic ill health was taking place around the same time, most 
notably Kazak’s influential paper developing a family systems model of adaptation and challenge (84), 
the uptake of the burden concept into paediatrics is a logical progression.   
 
Of the work conducted in the field of parental burden, the adaptation of the burden concept to suite the 
paediatric population has been pivotal.  Undertaken by Raina et al, the group performed an extensive 
literature review of the paediatric and relevant geriatric caregiving literature and concluded that much 
of the work in the paediatric field was not based upon a reliable theoretic framework. They also 
concluded that the literature had failed to provide a comprehensive picture of caregiver health in the 
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population, specifically by lacking investigation of both the direct and indirect relationships between the 
various factors responsible for caregiver burden (103).  In response to their findings, Raina et al created 
a new model of caregiver burden by combining those of Pearlin et al (88), Wallander et al (110) and King 
et al (111); by creating a hybrid model the authors hoped to give a more complete picture of caregiving, 
including areas from both the paediatric and adult literature, and expanding on the concepts introduced 
by previous authors.   Their model, the caregiving process and caregiver burden model, shown in figure 
2.1, differs from those previously mentioned in a number of ways: 
 the authors attempted to focus on both the formal and informal caregiving process within the 
single model;  
 they delineated child disability and child behaviour into two individual constructs; 
 inclusion of two new constructs; family function and social support aimed to examine the socio-
ecological concept of King et al (111) and finally;  
 delineating caregiver health into physical health and psychological health.   
 
In this model it is important to be aware of the uni-directional arrows depicting the causal relationships 
between the various factors.  The authors recognised that in some of these cases the relationship is in 
fact bi-directional, however, they maintained the use of uni-directional relationships due to later ease in 
testing of the model, and depicted the direction of association which had the most evidence in the 
literature (103).  
 
In a subsequent study Raina et al. tested their model on 468 caregivers of children with cerebral palsy.  
Each of their constructs was covered through the use of a self-report questionnaire followed by a  
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Figure 2.1 The Conceptual Model of Caregiving process and Caregiver Burden among Paediatric 
Population; the hypothesised primary constructs and their interactions (Raina et al, 2004) 
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structured interview, consisting of items from various pre-tested measures.  Using factor analysis and 
structural equation modelling refinements were made to the original hypothesised model, significantly  
the removal of the perception of formal care construct (E in fig 2.1) due to missing and non-applicable 
answers to the questionnaire covering the construct variable, and removal of the child function 
construct (B in fig 2.1) due to strong correlation with the caregiving demands construct.  The final model 
(figure 2.2) consisted of nine constructs with a total of twenty three variables and was considered to 
have a good fit with Bentler and Bonett’s Nonnormed Fit Index (NNFI) of 0.90 and a Bentler’s 
Comparative Fit Index (CFI) of 0.92. Using this model the best predictors of caregiver well being were 
child behaviour, caregiving demands and family function (103,112)  
 
Care should be taken in interpreting the results of this study, as the model was tested using caregivers of 
children with cerebral palsy it should not be assumed that it is suitable for all childhood chronic health 
problems.  For example, it was reported that higher levels of child behaviour problems were associated 
with lower levels of caregiver psychological (β = -0.22) and physical (β = -0.18) health; although clearly 
relevant for cerebral palsy, this may be less so for non-developmental disorders such as CF or diabetes 
mellitus etc.   
 
Despite this, the model has been used in a literature review examining burden in parents of paediatric 
oncology patients.  The authors reviewed a total of fifty seven articles which examined factors related to 
caregiver health using validated self-report measures, which included paediatric oncology patients.  
They then studied the articles’ findings to identify whether their conclusions would fit into the 
theoretical model by Raina et al (103), for example they found that six of the studies reported that child 
behavioural problems contributed to caregiver well being, therefore providing evidence that this aspect 
of the model proposed by Raina et al (103) also held true for oncology patients.   The authors found 
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evidence for all but two of the variables outlined by Raina et al (103).  Those variables evidence did not 
exist for were “perceptions of formal care” and “physical health”.  Lack of evidence to support the 
variable “perceptions of formal care” is, in fact, of little consequence as this variable was later removed 
by Raina et al following testing of the model by factor analysis (112).  With regards to the physical health 
variable the authors stated that little research had been done in this area within the oncology literature, 
and acknowledge that it is likely that the physical health of parents caring for children with cancer could 
be affected by their caregiving situation.  In addition to these two variables the authors found minimal 
evidence to support the self perception variable; but did identify studies which showed that 
psychological distress could be related to low mastery, higher repressive adaptation and performance 
assertiveness, and so accepted that self perception was a relevant variable.  The authors concluded that 
aspects of the caregiving process and caregiver burden model were well supported by the paediatric 
oncology literature, but that there were areas requiring further research.  In their conclusion they also 
called for the use of theoretical models to guide research as they had found that less than half of the 
articles they reviewed had used a theoretical model.  Furthermore, they stressed the importance of 
undertaking longitudinal rather than cross-sectional studies in order to identify the casual pathways 
between the various variables attributable to caregiver health (113).   
 
This review does indicate that the caregiving process and caregiver burden model is likely to be 
transferable to multiple chronic illness situations within the paediatric population, including CF.  It 
would, however, need to be tested under each new situation it was intended to be used in, but, it is a 
step closer to reaching a consensus with regard to the complex array of variables at play in the area of 
caregiver burden and health.  
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2.4 Burden of Care in Cystic Fibrosis 
 
 
The presence of treatment burden in CF has been acknowledged in the literature, but there have been 
few attempts to study it directly.  There is evidence to suggest that it follows the same patterns as in the 
geriatric and paediatric literature.  As in other paediatric chronic illnesses, it has been consistently 
shown that mothers of children with CF undertake the majority of the caregiving (114), and that they 
may experience similar outcomes as a result of their caregiving, including depression and anxiety, 
feelings of guilt and disrupted family and social lives (114,115). Furthermore, as in other areas of the 
literature it has been demonstrated that these outcomes may be moderated by the level of family 
support (116), but are not affected by disease severity as measured by FEV1 (109,116).  The literature 
has disagreed on whether child age plays a role (109,117).    Many other areas of caregiver burden in CF 
have been largely unaddressed, particularly if using the caregiving process and caregiver burden model 
by Raina et al (103) to guide which areas are examined.   
 
An area which has recently received attention is the issue of the amount of time that CF patients spend 
on treatments each day; as previously discussed the routine day to day, treatment for a patient with CF 
can be extensive, incorporating numerous medications and routines to tackle the multi-system nature of 
the disease.  It is this aspect of CF which is likely to put the most pressure on families, and this is seen in 
the literature reflecting the difficulties families experience adhering to the often complex regimens.  
Ziaian et al have conducted a study comparing the amount of time children with CF, diabetes and 
asthma spend on their treatments each day, the level of hassle to complete their treatments and the 
impact this may have on their HRQOL.    Enrolled in the study were 48 children (aged 10-16) with CF, 54 
with diabetes, and 58 with asthma.  Data on treatment tasks and treatment hassle were collected by 
telephone interview with both the parent and child recalling all the treatment activities in the previous 
 
 
45 
 
Action 
Research 
24 hours, including the nature of the treatment, time of commencement, time to complete the task, and 
the level of hassle experienced by the child (measured on a four point scale).  Assessments occurred on 
three occasions, at baseline and at one and two years, each assessment consisted of three telephone 
calls; two weekdays and one weekend.  During the assessment period the children and parents also 
completed the relevant versions of the Child Health Questionnaire (CHQ).   
 
The children with CF reported a mean number of 5.8 ± 1.7 treatments per day lasting a mean of 73.6 ± 
57.0 minutes, this differed from their parents who reported a mean number of 4.0 ± 1.8 treatments per 
day lasting a mean of 59.6 ± 45.2 minutes; the difference could be explained by the children 
overestimating their treatments or reflect treatment which takes place at school and therefore the 
parents do not report this.  Never the less, it reflects that parents and children with CF spend 
approximately an hour a day in treatment tasks.  The children with CF also spent significantly longer on 
their treatments than their counterparts with diabetes or asthma (p<0.001).  In all the groups, both 
children and parents rated the level of hassle as low, although those with diabetes and CF described 
significantly higher hassle than those children with asthma (p<0.001).  The children with CF ranked their 
hassle as 0.8 ± 0.7, and their parents slightly higher at 0.9 ± 0.7, however, as the measure used to rank 
hassle is not described by the authors past being a four point Lickert scale, it is unlikely to be validated, 
and so drawing conclusions from these values is difficult.    The authors also examined the relationship 
between the children’s disease severity as measured by FEV1 and the time spent on treatments, the 
number of treatments and hassle per treatment, and found that the time spent on treatment correlated 
with FEV1 using Pearson’s correlations when using  both the parents (-0.41 p<0.01) and children’s (-0.36 
p<0.05) reports (98).   
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A similar study has been conducted in adults with CF, examining the number of treatments and the time 
taken to complete their treatments, but also their treatment burden as measured by the three burden 
items included in the Cystic Fibrosis Questionnaire (CFQ).  Two hundred and four participants completed 
the CFQ and surveys designed by the authors detailing the treatments they had undertaken the previous 
day.  The median number of treatments reported each day was 7 (5-9), taking a mean time of 108 ± 58 
minutes to complete.  This is greater than the time reported by the paediatric population, and could be 
a result of a number of factors; however, as it is likely to reflect the progressive nature of CF, with 
treatment requirements increasing over time.  The mean CFQ burden score for the population was 52.3 
± 22.1 out of a possible score of 100, with lower scores reflecting higher burden, with reporting more 
treatment activities increasing the level of burden experienced.  Specifically, when controlling for age, 
gender and FEV1, the use of two or more nebulised therapies and spending more than 30 minutes on 
physiotherapy per day was associated with a significantly increased level of burden (118).  
 
Although this study looked at the patients themselves rather than caregivers, it is easy to see that if it 
were a parent spending 108 minutes per day administering treatments to their child then there may be 
a significant burden placed on that parent, particularly if coupled with the risk factors identified for 
experiencing burden such as lack of social support or low socioeconomic status.    
 
An attempt has been made to develop a measure to examine caregiver well being in CF – the Caregiver 
Quality of Life Cystic Fibrosis (CQOLCF) scale, which was modified from the Caregiver Quality of Life 
Index – Cancer by Boling et al (119)  The CQOLCF is a 35 item index using a five point Lickert scale to 
measure the physical, emotional, social/family and functional well being of CF caregivers.  The index was 
validated using the Beck Depression Inventory (BDI) and SF-36.  The CQOLCF correlated with the mental 
component any physical component summary scores of the SF-36 (p<0.01), but it showed poor 
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correlation with the BDI.  There was also no relationship between the CQOLCF score and FEV1 (119).  The 
measure has only been used by the author since its completion, and with questionable results (120).   
 
As such, there is currently no reliable measure of caregiver well being and burden in CF, and no CF 
specific conceptual model to guide research.   
 
 
 
2.5 Development of the Challenge of Living with Cystic Fibrosis Measure 
 
 
The development of the Challenge of Living with Cystic Fibrosis (CLCF) measure began in March 2005 in 
response to clinician interest and concern in the number and complexity of caregiving tasks carried out 
by parents of children with CF. Its development attempted to address the current gap in the literature 
which exists with regard to assessing the burden placed on caregivers of children with CF. The aim of the 
CLCF is to provide a method of quantifying the time, effort, meaning and ease of management of this 
chronic condition in children up to and including thirteen years of age. The process started with a 
consultation with the CF team at Alder Hey Children’s Hospital, Liverpool which produced a score sheet 
listing each of the possible medications and an estimate of the time taken to administer each.  The 
diagram Fig. 2.1, adapted from Glasscoe et al. (121) demonstrates the stages of development of the 
questionnaire. The CLCF has been developed in accordance with the [American] Food and Drug 
Administration’s (FDA) criteria for creating measures to be used as endpoints in clinical trials (122). 
 
Following this initial discussion, eight caregivers of children under the age of fourteen with CF in the 
Alder Hey clinic, took part in a focus group.  This first focus group examined the caregivers’ view of living 
with CF, their families’ experiences and the development of a number of themes they felt were central 
to managing CF within their family. It was at this point that the caregivers expressed their dislike of the 
 
 
48 
 
Action 
Research 
term burden, feeling it implied that their child was a burden, and instead described living with CF as a 
challenge, and as such this became the title of the questionnaire.  Therefore, the term challenge in the 
title of the questionnaire simply reflects the parents dislike of the term burden; the questionnaire itself 
remains a measure of burden, and “challenge” is simply a more acceptable proxy for this.  From this 
meeting a thematic analysis was conducted in order to provide the skeleton for the draft questionnaire.  
This group then reconvened as an action research group, with the group expanding on, and further 
defining the themes selected in the first meeting, using the items from the thematic analysis to 
construct questions for the questionnaire.   
 
 “Taking into account context and circumstances; 
  Home-based management: 
- establishing and maintaining routines 
- keeping child well and preventing decline 
- managing & coordinating tasks in a complex network 
 Salient ways to keep the routine running smoothly; 
 Areas of life where CF negatively impacts; 
 The ‘well’ routine 
- dietary management 
- physiotherapy and airway clearance 
- treatments for respiratory infections and 
 Hospital-based management 
- out- patient care 
- the ‘poorly’ routine.” (123) 
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A second focus group of three caregivers critiqued this first draft measure; it was then piloted with 
seven caregivers to assess its face validity and acceptability, and distributed to the CF professionals for 
comment.   
 
Cognitive interviews with nine caregivers, naïve to the development process so far, were conducted to 
estimate understanding of the questions on the questionnaire, and so refine the measure.  A ‘verbal 
probing’ technique (124) assessed the content, form and structure of the draft questionnaire, and 
individual questions were assessed for clarity, recall window, judgment and response set. The analysis of 
the cognitive interviews was based upon four psychological aspects of the questionnaire – 
comprehension, retrieval, response set and value judgments.  The CLCF was revised six times over the 
seven interviews in response to the answers given by participants.         
 
Following the refinement of the questionnaire, a pilot study with thirty participants was conducted to 
identify floor and ceiling effects, and test-retest stability, with participants completing the questionnaire 
at two time points seven days apart.   Internal consistency of individual subscales and overall scores 
were established with Chronbach alpha and Gottman split-half reliability coefficients.  Also performed at 
this time was a preliminary validation of the measure, assessing convergent validity with the three 
burden items on the CFQ, and divergent validity with a hypothesised variation in the caregiver challenge 
between three age groups, and one versus two caregivers.  Finally, the CLCF was examined for an 
association between lung function as measured by FEV1 and the measures individual subscales, and also 
the ability to discriminate between those with and without P. Aeruginosa, in order to assess its use as a 
proxy for disease severity (125).   
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The next steps in the development of the CLCF, as demonstrated in the diagram below are the 
psychometric analysis via factor analysis, and a study of the measure’s responsiveness, which is the 
subject of this thesis. 
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Fig 2.3 Flow diagram outlining the development process of the CLCF 
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Chapter Three 
Responsiveness of the Challenge of Living with Cystic Fibrosis 
Questionnaire 
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The Responsiveness of the Challenge of Living with Cystic Fibrosis 
Questionnaire 
 
 
3.1 Introduction 
 
 
The Challenge of Living with Cystic Fibrosis (CLCF) Questionnaire has been developed to address the gap 
in the literature which exists with regard to assessing caregiver well being and burden in CF.  It has been 
shown that both children and adults with CF spend a considerable amount of time daily undertaking 
treatment tasks (98,118) and that this, along with the number and complexity of the tasks undertaken, 
has an impact on adherence to treatment regimens (51-53) .  Furthermore, the time spent on, and the 
nature of caregiving tasks is an important variable within the burden of care concept and has been 
shown to have a direct relationship with both the psychological and physical health of caregivers of 
children with chronic illness (112).  This coupled with evidence that caregivers of children with CF 
experience depression, anxiety, and a disrupted family and social life (114,115), supports the need for a 
measure such as the CLCF. 
 
Unlike some other measures, the CLCF aims to have a place both in research and in the routine clinical 
environment.  As the CLCF has been developed in accordance with the FDA guidelines (122) on patient 
reported outcome measures for use in clinical trials, the CLCF can be used as a secondary endpoint in 
clinical trials, in a similar manner to which HRQOL measures have been utilised (126,127). That is, in 
intervention trials, to assess the additional burden which potential new treatments may place on 
primary caregivers of children with CF.  This is particularly important in light of the increasing complexity 
of treatments being conducted at home, for example the administration of IV antibiotics at home by 
parents.   
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As mentioned above, the CLCF aims, not only to be applicable in research, but also in the clinical setting, 
and it is for this circumstance that assessing the measure’s responsiveness is of most importance.   To be 
a useful clinical tool the measure must respond to changes in a patient’s clinical status, as it is this which 
is most likely to govern the number, duration and complexity of treatment tasks undertaken by the 
patient’s parents.  And so, in line with the burden of care concept, the patient’s clinical status is a 
predictor of the degree of burden experienced by the parents, and therefore, any change in clinical 
status may result in a change in the level of burden. 
 
Responsiveness to change has been argued to be an important aspect of validity, and can be described 
as the ability of a QOL measure to reflect the effects of a clinical intervention, or in this case, the effects 
of a change in a child’s health (128).  As well as providing evidence for the measure’s validity, 
responsiveness is also important in determining whether a measure is clinically useful (129). It is the aim 
of this research project to ascertain whether the CLCF identifies a change in the burden experienced by 
parents at a time when their child’s health has declined, namely, during a period of pulmonary 
exacerbation, and in this way assess the measure’s responsiveness.  
 
 
3.2 Objectives 
 
 
3.2.1 Project aim 
 
The main aim of the study is to establish whether a decline in a child’s clinical condition results in an 
increased caregiver burden as measured by the CLCF questionnaire. And, in this way, determine its 
responsiveness to change, and assess its usefulness in the questionnaire in a clinical setting. 
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3.2.2 Hypotheses 
 
The hypotheses (Hn) to be tested along with the corresponding null hypotheses are listed below: 
 
H1 There will be a difference in the number of minutes per day spent carrying out caregiving tasks 
between time point one (well) and time point two (unwell).  It is expected that a decline in a child’s 
clinical status will result in an increase in the time spent in caregiving tasks. 
H0 There will be no difference between the time points in the number of minutes per day spent in 
caregiving tasks. 
 
H2 There will be a difference in the parents’ estimate of average effort expended on caregiving tasks 
between time point one and time point two.  It is expected that a decline in a child’s clinical status will 
result in an increased estimate of the effort required. 
H0 There will be no difference in the parents view of the effort expended in caregiving tasks 
 
 
 
3.3 Methods 
 
 
3.3.1 Ethical Approval & Honorary Contract 
 
Ethical approval for the development and preliminary validation of the CLCF, including the sensitivity 
study, was granted by Liverpool Children’s Ethics Committee (see appendix 3.1).  In order to take part in 
the development, and perform the sensitivity study I was granted an honorary research contract with 
Alder Hey Children’s NHS Foundation Trust (see appendix 3.2).  The project was funded by the grant for 
the overall development of the CLCF, awarded to C Glasscoe, from the Alder Hey Children’s NHS 
Foundation Trust (see appendix 3.3). 
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3.3.2 Study Design 
 
The sensitivity study was carried out within the context of a larger three-centre validation study for the 
CLCF, with the final aim of the validation study being a factor analysis.  A prospective, longitudinal, 
crossover design using families from one centre was chosen to assess the sensitivity of the CLCF.  
Caregivers of children with CF were asked to complete the study questionnaire and the validation 
measures at two time points, once when their child was “well” and again when their child was “unwell”.  
At the time of recruitment (Time 1) the children fell into two groups; those scoring <2 on the Pulmonary 
Exacerbation score (well) and those scoring ≥2 (unwell); each caregiver was asked to complete the study 
questionnaire and validation measures for time 1 and return them by prepaid post.  The caregiver was 
instructed to keep the time 2 questionnaires until their child went from being “well to unwell” or 
“unwell to well”, depending on their status at time 1.  As such, the study period for each child was 
different, depending on the length of time for their clinical status to change (see figure 3.1). 
 
 
3.3.3 Recruitment 
 
The population for this study came from the approximately n=200 families with children with CF 
registered at Alder Hey Children’s Hospital or one of its peripheral clinics.  Eligible participants (see 
inclusion/exclusion criteria below) were identified from clinic lists attended by the researcher, and 
approached in person during their clinic visit.  At this time the research study was explained to them, 
and if appropriate, their child, and they were provided with the participant information pack containing: 
 Letter of invitation (appendix 3.4) 
 Caregiver information document (appendix 3.5) 
 Patient information document (children aged ≥7) (appendix 3.6) 
 Consent form (appendix 3.7) 
 Assent form (children aged ≥7) (appendix 3.8) 
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 Time point one questionnaires 
 Time point two questionnaires 
 Two prepaid addressed envelopes. 
 
Each eligible participant was invited to take the information pack home to review the pack before 
making a decision whether to take part in the study.  They then received a follow-up phone call the next 
week to confirm their decision.  If they consented to take part, they were asked to return the time one 
questionnaires with the consent form, and if appropriate the assent form, within the next two weeks.   
 
Those participants who verbally consented but did not return the questionnaires received two further 
follow-up phone calls at one and two months respectively, and were also approached at routine clinic 
appointments.  Those participants who returned time point one questionnaires received phone calls at 
one and two months post return, as well as reminders during routine clinic appointments.  A letter 
(appendix 3.9) with a second set of time two questionnaires was sent two months prior to the study 
closing.   
 
Inclusion and Exclusion Criteria 
One parent of each eligible child was invited to be included in the study.  Families were eligible if their 
child was aged ≤13 with a confirmed diagnosis of CF for at least one year.   Families were excluded if: 
 either parent had a physical or mental illness that rendered them incapable of providing care for 
the child with CF; 
 there were complex social problems and the study might disrupt child protection plans; 
 where there was a significant learning disability and 
 where English was not the caregiver's first or second language. 
 
 
58 
 
Action 
Research 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Study Protocol for the CLCF sensitivity study 
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3.3.4 Sample Selection 
 
The sample was gathered from Alder Hey Children’s Hospital and four of its nine peripheral clinics; 
 Arrow Park*; 
 Chester*; 
 Isle of Man; 
 Leighton; 
 Ormskirk*; 
 Warrington* 
 Wigan ; 
 Whiston and 
 Wrexham.  
 
This gave a total of five sites.  The clinics were selected on the basis of distance from the Alder Hey site 
and the day on which the clinic was held (as some sites held their clinics at the same time).  At each site 
a full clinic list was obtained and eligible families identified.  Repeat visits were then made to each clinic 
until every eligible family had received information on the study.  At one site (Ormskirk) this was not 
possible due to the organisation of the clinic and time constraints, and only three eligible families were 
informed of the study.   
 
 
3.3.5 Outcome measures 
 
Validation 
As described above this study was also part of a larger validation study for the CLCF and as such the 
study participants also had to complete the questionnaires for the validation aspect of the larger study. 
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3.3.5.1 The Cystic Fibrosis Questionnaire – Parent (CFQ) 
 
The CFQ-Parent (appendix 3.10) is a disease specific measure for parent’s to report their child’s HRQOL; 
it is intended for parents of children aged six to thirteen.  The measure covers four general domains - 
physical symptoms, emotional functioning, vitality and school functioning; and seven CF-specific 
domains - eating disturbances, body image, treatment burden, respiratory symptoms, digestive 
symptoms and weight, and takes approximately 15-20 minutes to complete (130).  In the current setting 
the items of most interest are those concerned with treatment burden. The measure has been well 
validated, including a factor analysis which supported the structure of the measure, a full psychometric 
evaluation demonstrating internal consistency coefficients greater than 0.7 and good reproducibility 
(r=0.95), and the ability to differentiate between illness severity according to Shwachman scores 
(131,132) (133).  It is a widely accepted measure and has been uses as an endpoint in numerous studies 
(134,135). 
 
 
3.3.5.2 The Beck Depression Inventory (BDI) 
 
The BDI (appendix 3.11) is a tool to identify and measure the severity of depression in adults.  It was first  
published by Beck in 1961(136), and has undergone two revisions to develop it to its current version, the 
BDI-II, published in 1996 (106).  The BDI-II contains 21 items, scored from zero to three, and covers a 
range of items intended to reflect the diagnostic criteria for major depression as characterised in the 
*American Psychiatric Association’s+ Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-
IV).  During the validation of this measure it was found to have good correlation with the BDI-IA (r=0.93, 
p<0.001) and also with the Hamilton Depression Rating Scale (r=0.71), it was also shown to have high 
internal consistency (α=0.91) (137).  The measure’s sensitivity and specificity was examined by Dozois et 
al and found to be 81% sensitive and 92% specific (138).  The measure has been widely used, and has 
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been employed as a screening tool for depression in the general population (139-141).  This is being 
used as depression is a widely accepted negative outcome of the caregiving experience (71,92) 
 
 
3.3.5.3 The State -Trait Anxiety Inventory (STAI-Y) 
 
The STAI-Y (appendix 3.12) measures the presence of chronic generalised (trait) anxiety and temporary 
(state) anxiety. Developed by Spielberger et al in 1970, it contains two scales of 20 items each and the 
scores have a direct interpretation (142).  It was validated using correlations with the Taylor Manifest 
Anxiety Scale (r=0.80) and the Multiple Affect Adjective Check List (r=0.52) (143), and has been reported 
to have a stable factor structure (142,144).  Anxiety is a reported negative outcome of the caregiving 
experience (105) 
 
Responsiveness 
 
 
3.3.5.4 The Pulmonary Exacerbation (PEC) Score  
 
The PEC score (appendix 3.13) is used to identify the point at which a child transfers from the well state 
to the unwell state, and therefore prompting the completion of the second time point. The child is 
considered well if they score less than two on the PEC score, and unwell if they score two or more and 
are taking back-up antibiotics.  The maximum score is six, with each of the criteria on the PEC score 
marked as one: 
 decreased exercise tolerance; 
 increased cough; 
 increased sputum; 
 presence of crackles or wheezes on auscultation; 
 missing school or nursery and 
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 weight loss 
 
 
3.3.5.5 Forced Expiratory Volume at one second (FEV1) 
 
FEV1 is considered to be the gold standard in assessing a patients’ lung function at any given time.  In 
those children old enough to perform spirometry, their FEV1 was recorded from the nearest clinic 
appointment to the time at which the questionnaires were completed, providing a record of their lung 
function at the well and unwell time points.  
 
 
3.3.5.6 CLCF – Minutes per Day and Average Effort 
 
At the current time no scoring system has been developed for the CLCF as a whole, and it is 
controversial as to whether one should exist due to the complex nature of the burden of care concept.  
Therefore one of the subscales, rather than the whole questionnaire needed to be identified as a proxy.  
It was decided that the minutes per day section, that is the total time parents estimate they spend doing 
treatments with their child, would be the best item to use as this is in line with other recent work 
conducted in the field of caregiver burden in CF (98,118).  Also to be used is the average effort as rated 
by the parents on a one (minimal effort) to three (high effort) Lickert scale for each of the treatments 
they administer. Both the minutes per day and effort sections of the CLCF are found on page eight of the 
questionnaire (see appendix 2.1, page 113).  As such all of the data for statistical analysis of the CLCF will 
be collected from this page alone. 
 
 
3.3.6 Statistical Analysis 
 
Results were analysed using SPSS version 17.0 and Stats Direct version 2.6.8 for Windows.  To describe 
the data mean and standard deviation (SD) was used where the data was normally distributed, and 
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median and interquartile range (IQR) where it was skewed.  To compare time points, the paired t-test 
was used for normally distributed data; for skewed data the Wilcoxon signed ranks test was used.  The 
data relating to the CLCF (minutes per day and effort expended) were unable to be analysed using non-
parametric methods, and were transformed, using square root transformation, to allow parametric 
analysis.   Statistical significance was taken as p<0.05 with a 95% confidence interval (CI).  A Bonferroni 
correction was applied to the p-value where multiple comparisons were made (see appendices 3.14 and 
3.15).  
 
3.4 Results 
 
 
3.4.1 Study Population 
 
Of the approximately 200 families of children with CF registered at Alder Hey Children’s Hospital or its 
peripheral clinics, 86  eligible families were contacted.  Of these 84 (97.7% of those contacted) gave 
verbal consent, whilst two (2.3%) families refused consent; one family due to the personal nature of the 
validation questionnaires, and the second family due to the time required to fill in the questionnaires.  
One (1.2%) family later withdrew due to illness in the main caregiver.  Nineteen (22.1%) families 
completed time point one only, and thirteen (15.1%) families completed both time points one and two. 
The remaining 51 (59.3%) families were lost to follow up.  This gives a final recruitment rate of 15.1% 
(see figure 3.2).   
 
Of the final study sample of thirteen, six (46.2%) families came from the Alder Hey clinic, four (30.8%) 
came from the peripheral clinic of Arrow Park, and one came from each of the clinics in Chester (7.7%), 
Ormskirk (7.7%) and Warrington (7.7%) (see figure 3.3).   
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Figure 3.2 Study Sample Selection Process 
 
 
 
 
 
 
Figure 3.3 Pie chart outlining the proportion of patients recruited at each centre 
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Routine data were collected at time one for both the parents and children in the study group (n=13) and 
compared to the group who completed time one only (n=19).   Data collected for the parents included 
their relationship to the child, their age and marital status, and markers of socioeconomic status.  Also 
compared were their BDI and STAI-Y scores in order to rule out the presence of depression or anxiety as 
a contributing factor for not returning the time two questionnaires and completing the study, thus 
introducing selection bias.  The parents’ characteristics at baseline are summarised in Table I, due to 
multiple testing, statistical significance was set at P<0.002 using the Bonferroni adjustment (see 
appendix 3.14).  There was no significant difference between those parents who completed time point 
one only and those who completed the study.   
 
Similarly, the children in the two groups were compared with regard to age, sex and markers of disease 
severity.  The child characteristics at baseline are summarised in Table II, again using a statistical 
significance level of P<0.002 (see appendix 3.15).  There was no significant difference between the 
children in the two groups. 
 
The study protocol (Figure 3.1) outlined a crossover design, whereby families would either follow the 
‘well-unwell’ arm or the ‘unwell-well’ arm, depending on their PEC score at time point one.  Of the 
thirteen families in the study group, five (38.5%) entered the ‘well-unwell’ arm and eight entered the 
‘unwell-well’ arm.   The median number of days to complete the study (and for the child’s PEC score to 
change from <2 to ≥2) was 68 (IQR - 29.5, 111.0).  There was no difference in the time taken to complete 
the study between the two arms (p=0.34).   
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¤ Statistical significance set at P<0.002 due to Bonferroni correction 
*BDI – Beck Depression Inventory (Beck,1996) 
**STAI – State Trait Anxiety Inventory (Spielberger) 
†median difference 
‡percentage difference 
 
 
 
Table I   Parent Characteristics at Baseline     
 
 
Completed T1  
and T2   (n=13) 
Completed T1 
 only    (n=19) 
Difference [95% CI]  P-value¤ 
Relationship to Child     
     Mother (n,%) 
     Father (n,%) 
13 (100%) 
0 (0%) 
17 (89.5%) 
2 (10.5%) 
10.5% (-13.9,31.8)‡ 
-10.5% (-31.8,13.9)‡ 
0.25 
0.25 
Parent Age (median,IQR) 38 (32,43.8) 36 (29.5,41.0) -3 (-9,2)† 0.44 
Marital Status 
     Single/never married (n,%) 
     Married (n,%) 
     Divorced (n,%) 
     Separated (n,%) 
     With a partner (n,%) 
     Missing (n,%) 
 
0 (0%) 
8 (61.5%) 
2 (15.4%) 
0 (0%) 
2 (15.4%) 
1 (7.7%) 
 
1 (5.3%) 
9 (47.4%) 
1 (5.3%) 
1 (5.3%) 
7 (36.8%) 
0 (0%) 
 
-5.2% (-25.1,18.7)‡ 
14.2% (-20.9,45.5)‡ 
10.1% (-12.8,38.5)‡ 
-5.2% (-25.1,18.7)‡ 
-21.5 (-48.4,11.7)‡ 
 
 
0.99 
0.33 
0.30 
0.99 
0.15 
 
Education 
     Some secondary school or less (n,%) 
     GCSE’s/O Levels (n,%) 
     A/AS Levels (n,%) 
     Other higher education (n,%) 
     University degree (n,%) 
     Professional qualification or postgraduate study (n,%) 
     Missing (n,%) 
 
2 (15.4%) 
3 (23.1%) 
0 (0%) 
4 (30.8%) 
1 (7.7%) 
2 (15.4%) 
1 (7.7%) 
 
1 (5.3%) 
4 (21.1%) 
1 (5.3%) 
5 (26.3%) 
4 (21.1%) 
4 (21.1%) 
0 (0%) 
 
10.1% (-12.8,38.5)‡ 
2.0% (-26.5,33.7)‡ 
-5.2% (-25.1,18.7)‡ 
4.5% (-26.2,36.9)‡ 
-13.4% (-38.1,16.1)‡ 
-5.7% (-32.2,25.4)‡ 
 
0.30 
0.99 
0.25 
0.99 
0.38 
0.99 
 
Employment 
     Seeking work (n,%) 
     Working full or part time (n,%) 
     Full time home maker (n,%) 
     Not working for other reasons (n,%) 
     Missing (n,%) 
 
1 (7.7%) 
10 (76.9%) 
1 (7.7%) 
0 (0%) 
1 (7.7%) 
 
1 (5.3%) 
9 (47.4%) 
6 (36.1%) 
3 (15.8%) 
0 (0%) 
 
2.4% (-18.9,29.4)‡ 
29.6% (-5.8,57.2)‡ 
-23.9% (-48.9,6.9)‡ 
-15.8 (-38.0,9.2)‡ 
 
0.99 
0.09 
0.11 
0.13 
Family Size 
     Number of children (median, IQR) 
     Number of children with CF (median, IQR) 
          One (n,%) 
          Two (n,%) 
 
 
2 (1,3)  
 1 (1,1) 
12 (92.3%) 
1 (7.7%) 
 
2 (1,2) 
1 (1,1) 
18(94.7%) 
1 (5.3%) 
 
0 (0,1)† 
0 (0,0)† 
-2.4% (-
29.4,18.9)‡ 
2.4% (-18.9,29.4)‡ 
 
0.19 
0.69 
0.99 
0.99 
BDI score* (median, IQR) 
 
4 (1.5,12) 
 
7 (1,15) 
 
1 (-3,7)† 
 
0.60 
 
STAI** state anxiety (median, IQR)   38 (29,45) 36 (24,45) 2 (-7,9)† 0.62 
STAI** trait anxiety (median, IQR) 37 (30,42.5) 31.5 (26.8,45) 3 (-4,9)† 0.55 
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¤Statistical significance set at P<0.002 due to Bonferroni correction 
†Median difference 
‡Percentage difference 
 
 
 
 
 
 
 
 
 
Table II   Child Characteristics 
at Baseline 
    
 
 
Completed T1  
and T2   (n=13) 
Completed T1  
only    (n=19) 
Difference  [95% CI] p-value¤ 
Age of Child - years (median, IQR)     
     1-4 (n,%) 
     5-9 (n,%) 
     10-13 (n,%) 
9.7 (4.8,12.9) 
3 (23.1%) 
5 (38.5%) 
5 (38.5%) 
 
5.1 (2.8,11.0) 
9 (47.4%) 
4 (21.1%) 
6 (31.6%) 
2.33 (-1.0,6.42)† 
-24.3% (-52.5,10.7)‡ 
17.4% (-14.3,48.4)‡ 
6.9% (-25.8,39.7)‡ 
0.29 
0.16 
0.27 
0.50 
 
Sex 
     Male 
     Female 
 
8 (61.5%) 
5 (38.5%) 
 
10 (52.6%) 
9 (47.4%) 
 
8.9% (-25.8,40.7)‡ 
-8.9% (-40.7,25.8)‡ 
 
0.51 
0.51 
Pseudomonas Status 
     Never infected (n,%) 
     No infection in 12 months (n,%) 
     Pseudomonas grown <50% months with 
cough swab (n,%) 
     Pseudomonas grown >50% months with 
cough swab (n,%) 
     
 
2 (15.4%) 
2 (15.4%) 
7 (53.8%) 
 
2 (15.4%) 
 
2 (10.5%) 
7 (36.8%) 
5 (26.3%) 
 
5 (26.3%) 
 
4.9% (-20.0,34.2)‡ 
21.5% (-48.4,11.7)‡ 
26.3% (-7.0,57.2)‡ 
 
-11.0% (-38.0,20.9)‡ 
 
0.99 
0.15 
 
0.09 
0.43 
Schwacmann Score at last Annual Review  
(median, IQR) 
     70-79 (n,%) 
     80-89 (n,%) 
     90-100 (n,%) 
     Missing (n,%) 
 
 
90 (86.3,95.0) 
1 (7.7%) 
6 (46.1%) 
5 (38.5%) 
1 (7.7%) 
 
95 (90.0,95.0) 
1 (5.3%) 
4 (21.1%) 
11 (57.9%) 
3 (15.8%) 
 
0 (-5,5)† 
2.4% (-18.9,29.4)‡ 
25.1% (-7.9,55.1)‡ 
-19.4 (-50.1,15.9)‡ 
- 
 
0.80 
0.99 
0.15 
0.31 
 
Chest X-Ray score at last Annual Review 
(median, IQR) 
 
 
1 (0.75,4.5) 
 
 
2.0 (1.0,3.0) 
 
 
0 (-2,3)† 
 
 
0.66 
 
FEV1 at last Annual Review (median, IQR) 
 
78.5 (64.5,96.5) 
 
77.0 (64.3,95.0) 
 
15 (-3,159)† 
 
0.17 
 
FEV1 (%) at Recent Clinic (median, IQR) 
 
83.0 (76.5,92.5) 
 
68.5 (58.8,78.8) 
 
34 (0,178)† 
 
0.008 
 
 
Pulmonary Exacerbation Score 
     <2 (n,%) 
     ≥2 (n,%) 
 
5 (38.5%) 
8 (61.5%) 
 
11(57.9%) 
8 (42.1%) 
 
-19.4% (-50.1,15.9)‡ 
19.4% (-15.9,50.1)‡ 
 
0.31 
0.31 
 
 
68 
 
Action 
Research 
3.4.2 Change in Clinical Parameters 
 
In order to take part in the second phase of the study, the children had to demonstrate a change in their 
clinical status as measured by the PEC score.  All children scored zero on the PEC score at the time they 
were well, with a mean (s.d) score of 3.62 (0.77) when they were unwell.  If the child attended clinic 
within two weeks of returning the time two questionnaires, their FEV1 and weight was recorded at this 
time.  This occurred in all but one patient.  The change in clinical parameters between the well and 
unwell time points is summarised is Table III; there was no significant change in either FEV1 or weight 
between time points.  
 
 
†Paired mean difference 
 
 
3.4.3 Change in Questionnaire Responses 
 
Parents completed the BDI and STAI-Y at both the well and unwell time points.  Their scores are 
summarised in Table IV; there was no significant difference in depression or anxiety between time 
points.  BDI scores were stratified as <13 or ≥13 as this is the cut off for mood disturbance.  BDI score is 
missing at the unwell time point for one patient due to return of the CLCF only at this time point.  
 
 
 
 
 
 
Table III Clinical Parameters at Well and Unwell Time Points     
 
 
Well (n=13) Unwell (n=13) Difference [95% CI] P-Value 
Pulmonary Exacerbation Score (mean,s.d) 
     
0.00 (0.00) 3.62 (0.77)  -3.61 (-4.08,-3.15)† <0.001 
FEV1 (mean, s.d) 
      
92.3 (16.64) 82.22 (9.71) 10.22 (-3.43,23.87)† 0.12 
Weight in kg (mean,s.d) 31.2 (14.19) 32.9 (14.0) 0.24 (-0.90,1.37)† 0.65 
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* Beck (1996) 
**STAI – State Trait Anxiety Inventory (Spielberger) 
†Paired median difference 
‡Paired percentage difference 
 
 
The median (IQR) within-person difference for the BDI between the well and unwell time points was 1.5 
(0.0, 5.5).  For state anxiety the difference was 8.5 (-0.75,14.0) and for trait anxiety 2.0 (-2.3,8.0). 
 
The number of minutes per day and the average effort expended by parents in completing treatment 
tasks is summarised in Table V.  Both the minutes per day and the average effort scores were skewed 
(see figures 3.4 through 3.7) and so a square root transformation was used to normalise them, to allow 
parametric testing (see figures 3.8 through 3.11). 
 
 
Table IV   Depression and Anxiety Scores at Well and Unwell Time Points 
    
 Well (n=13) Unwell (n=12) Difference [95% CI] P-Value 
Beck Depression Inventory* (median, IQR) 
     <13 (n,%) 
     ≥13 (n,%) 
     Missing 
2.0 (0.0,12.0) 
11 (84.6%) 
2 (14.4%) 
0 (0%) 
5.5 (2.3,13.0) 
8 (66.7%) 
4 (33.3%) 
1 (8.3%) 
-2(-4,2) † 
15.1%‡ 
-15.4%(-46.1,19.8)‡ 
- 
0.30 
0.82 
0.68 
STAI** State Anxiety (median, IQR) 36.0 (28.0,36.5) 43.0 (31.25,49.5) -7 (-12.5,11.5)† 0.37 
STAI** Trait Anxiety (median, IQR) 36.0 (29.0,42.0) 40.0 (32.0,44.8) -2 (-6.5,6)† 0.38 
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Figure 3.4 Distribution of the number of minutes per day spent on treatment tasks at the well time 
point 
 
 
Figure 3.5 Distribution of the number of minutes per day spent on treatment tasks at the unwell 
time point 
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Figure 3.6 Distribution of the average effort expended in treatment tasks at the well time point 
 
Figure 3.7 Distribution of the average effort expended in treatment tasks at the unwell time point 
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Figure 3.8 Distribution of the number of minutes per day spent on treatment tasks at the well time 
point following square root transformation 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 Distribution of the number of minutes per day spent in treatment at the unwell time 
point following square root transformation 
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Figure 3.10 Distribution of the average effort expended in treatment tasks at the well time point, 
following square root transformation 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 Distribution of the average effort expended in treatment tasks at the unwell time point 
following square root transformation 
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*Pulmonary exacerbation score when unwell 
Although not statistically significant, there is an apparent difference between the well and unwell time 
groups with regard to the number of minutes per day spent in treatment tasks; this is displayed 
graphically in figure 3.12 and 3.15.  Figure 3.15 demonstrates the change in minutes per day, with the 
well values corrected to equal zero. To ease interpretation of figure 3.12, this has been split according to 
PEC score in figures 3.13 and 3.14. Figure 3.13 demonstrates that of the five patients in the PEC range 2-
3 four of the patients’ treatment time increased.     
Table V   Number of Minutes and Average Effort Expended on Treatment (Normalised 
Data) 
    
 
 
Well (n=13) Unwell (n=13) Difference [95% 
CI] 
P-Value 
Minutes per Day (Mean, SD) 
     PEC score 2-3* (n=5 ) 
     PEC score >3* (n=8 ) 
9.91 (5.23) 
11.11 (1.68) 
9.17 (6.61) 
12.69 (6.45) 
12.75 (2.74) 
12.66 (8.12) 
-2.78 (-5.78,0.22) 
-1.65 (-4.65,1.36) 
-3.45 (-8.60,1.62) 
0.07 
0.20 
0.15 
Average Effort (Mean, SD) 
     PEC score 2-3* (n=5 ) 
     PEC score >3* (n=8 ) 
1.22 (0.18) 
1.33 (0.24) 
1.12 (0.14) 
1.24 (0.25) 
1.43 (0.28) 
1.15 (0.11) 
-0.02 (-0.07,0.11) 
-0.95 (-0.15,0.34) 
-0.27 (-0.09, 0,03) 
0.62 
0.34 
0.36 
      
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 Parallel plot showing changes in the Minutes per Day spent on treatment tasks at the Well 
and Unwell time points 
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Figure 3.13 Parallel plot showing changes in the Minutes per Day spend on treatment tasks at the 
Well and Unwell time points for patients with a Pulmonary Exacerbation Score of 2-3  
Figure 3.14 Parallel plot showing changes in the Minutes per Day spend on treatment tasks at the 
Well and Unwell time points for patients with a Pulmonary Exacerbation Score of >3 
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Figure 3.15 Parrallel plot showing the change in Minutes per Day spent on treatment tasks, with the 
well time point corrected to equal zero 
 
 
In the PEC score range >3, five patients treatment times increased and one stayed the same; this leaves 
only three patients whose treatment times fell when they became unwell.  The general trend for an 
increase in minutes per day is maintained when stratifying for PEC score to differentiate between 
degrees of severity of the pulmonary exacerbation.   
 
There was no difference between the average effort expended on treatment tasks between the well and 
unwell time points, this was maintained when stratifying for PEC score. 
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The median (IQR) within person difference in minutes per day was 53.0 (-16.5,101.5), and effort was 
0.01 (-0.2, 0.1).  The within person difference in minutes per day correlated with the within person 
difference in effort (Spearman rho 0.624, p=0.024), displayed graphically in figure 3.16. This indicates 
that the concepts of time and effort are related.  Neither the difference in minutes per day or average 
effort correlated with the differences in BDI score, trait anxiety or state anxiety (see appendix 3.15).  
 
3.5 Discussion 
 
 
The overall aim of this study was to establish whether the CLCF responded to changes in a child’s clinical 
status, to determine its responsiveness and, as such, its usefulness in the clinical setting.  This was to be 
achieved through comparing the total minutes per day and the average effort parents spent in 
treatment tasks for their child at two time points; when their child was well, and again when they 
became unwell.  
Figure 3.16 Scatter plot showing the relationship between the Within Person Difference in Minutes per 
Day and Average Effort expended on treatment tasks 
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The principal positive finding from this study is the correlation between the within person difference in 
average effort and the within person difference in minutes per day (p=0.024) , suggesting that as the 
amount of time spent on treatment tasks increases, so the effort required to perform the tasks may also 
increase. There was a trend for the number of minutes per day parents spend on treatment tasks for 
their child to increase during a period of pulmonary exacerbation, but this did not reach statistical 
significance (p=0.07).  Despite this, with a median within person difference of 53 minutes per day, 
clinical significance is certainly a distinct possibility.    The severity of the pulmonary exacerbation, as 
measured by the PEC score, appears to have no effect on the difference in minutes per day.  There was 
no evidence of change in the average effort expended on treatment tasks between the two time points.   
 
There was no statistical change in depression or anxiety measured by the BDI and STAI-Y.  However, a 
trend towards an increase in parental depression when a child develops a pulmonary exacerbation is 
visible, with the median BDI score increasing from 2.0 when the child is well, to 5.5 when they are 
unwell.  This is also reflected in the increase in the number of parents scoring ≥13, the cut off point for 
mood disturbance, with the proportion doubling from 14.4% to 33.3%.  There was no correlation 
between the changes in minutes per day or average effort with changes either in depression or anxiety 
over the two time points.   
 
As stated above, the principal positive finding of this study has been the correlation between the within-
person difference in minutes per day and the within-person difference in effort (p=0.024).  Although not 
the aim of the study, or the anticipated outcome, this is an interesting finding, not described elsewhere.  
This has demonstrated, that the amount of time required to perform a task is related to the amount of 
effort needed to complete it.  However, effort is a complex entity, and difficult to define, and other 
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factors are likely to influence it, for example the time of day the task is being completed, how tired the 
person completing the task is, whether it is a new task, just being learnt, or a familiar one, performed 
many times before. Nevertheless, this is a further step to understanding burden, and, this is a finding 
which is not just important in terms of research, but is of relevance to the CF population in real terms, a 
relationship between time and effort is an effect which parents of children with CF will experience and 
feel, rather than an abstract research outcome; this is applicable in the same way that families 
experience their child being able to walk smaller distances, rather than appreciating a drop in their FEV1.   
This highlights the potential of this tool as a pragmatic outcome measure to assess treatment burden.      
 
The high level of non-response, corresponding low recruitment rate of just 15%, and subsequent small 
sample size, is the main weakness of this study.  A good response rate is generally considered to be 75% 
or above (145).  There are a number of factors which could also have contributed to the poor response 
rate, these factors largely relate to the questionnaires used; their number, length and content; but also 
to the study population itself.    
 
Referring back to figure 3.2, which outlines the study sample, it is clear that the initial response from 
families to the study was good, with 84 of the 86 families approached giving verbal consent to take part.   
As such, the question must be asked, what caused almost 85% families not to complete the study, when 
their first reaction to the proposed research was so positive?  The potential reasons can be summarised 
in figure 3.17, and are explained in full below. 
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Figure 3.17 Summary of Potential Factors Affecting the Study Sample Selection Process 
 
As mentioned above, the number of questionnaires participants were required to complete over the 
study period may have had an impact on the response rate.  Participants were required to complete a 
total of seven questionnaires over the two time points (four at time one and three at time two).  The 
time to complete all the questionnaires over the two time points could take from an hour and a half to 
two hours (106,125,130,143), not a small time commitment given that the majority of the parents in the 
study population, and in the those who only completed the first time point, worked either full or part 
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time (see Table I). As respondents were asked to post their questionnaires, this does not include the 
time taken to actually post the questionnaires, and so it is also possible that the questionnaires were 
filled in and simply not returned.   
 
Along with the number of questionnaires and the time required to complete them, is the issue of the 
length (number of pages) of the questionnaires.  Some research has shown that differences exist in the 
response rate between a one page questionnaire and a three page questionnaire (145).  The length of 
the questionnaire was not likely to be an issue for the CFQ (4 pages), BDI and STAI (2 pages), but the 
length of the CLCF (10 pages) may have been an influencing factor as to whether or not parents chose to 
complete the study.   
 
A further explanation for the low response rate is the personal nature of both the BDI and STAI-Y.  This 
was cited as a reason for non-participation in one of those parents who actively refused consent.  
Although happy to complete the CLCF and CFQ as those questionnaires were primarily about their child, 
the parent was unhappy answering questions about themselves, feeling they were unnecessary and 
unrelated to the research topic.  Although only raised by one parent, it is possible that others felt the 
same and simply chose not to complete the questionnaires rather than actively withdrawing from the 
study.   It has been reported that the perceived relevance of the questionnaire to the respondent can 
influence response rates (145). 
 
The first of the factors relating to the study population was the presence of questionnaire overload.    
The primary recruitment site for the study was Alder Hey Children’s Hospital, which was also the site at 
which the CLCF was constructed and pilot studies run, meaning that many of the eligible families had 
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completed the sensitivity study questionnaires on at least one prior occasion, with a minority of families 
completing it on numerous occasions throughout the development process.   
 
Although this partially explains the low response rate at Alder Hey, it does not explain the response rate 
at the peripheral clinics where the families were naive to the CLCF and its development.  The children 
included in the study were, as a rule, well children (see Table II) with a median Shwachman score at their 
last annual review of 90. This may be due to the level of care received, as it is increasingly the case that 
patients are “well” on a day to day basis, or it may be that only the parents of well children completed 
the study questionnaires; with the non-responders being parents of less well children.  As such, the 
characteristics of both parents and children were compared.  There was no statistical difference 
between the parents, or the children. However, those children whose parents completed the study did 
appear to have a better FEV1 at the time of recruitment (83%) than those who only completed time one 
(68.5%).  As well as affecting the response rate, this raises the possibility of selection bias in the sample, 
suggesting that those parents whose children were in better health were possibly more likely to 
complete the questionnaires than the parents of less well children.  This poses a problem as the reason 
for those parents not completing the questionnaire could have been due to a time issue – with those 
parents spending more time on treatments for their children.   This may have distorted the study 
sample, giving a lower estimate of the time or effort spent on managing their child’s CF, than that which 
exists within the whole population; response bias.   
 
A further demonstration of how well the population were as a whole is the P. Aeruginosa infection rate; 
only 15.4% having had a recent positive cough swab.   Furthermore, the mean FEV1 did not change 
markedly when they became unwell, and none of the participants required IV antibiotics as a result of 
their exacerbation, and only one was started on a nebuliser.   
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The final explanation refers to the loss to follow-up of patients between time points one and two.  As 
these parents had already completed the first set of questionnaires, it is possible that the above issues 
were not an impedance to their participation.  At this stage, the most likely explanation for non-
completion is the pulmonary exacerbation itself.  Either their child did not have a pulmonary 
exacerbation within the time frame of the study, therefore making it impossible to complete the second 
set of questionnaires, or, when that exacerbation did occur, the family were unable to complete the 
questionnaires due to the time and effort constraints of the exacerbation itself.   
 
An additional factor which complicates the interpretation of these results is the existence of the outlier 
visible in figures 3.12 and 3.14.  This is due to a parent whose estimated minutes per day spent in 
treatment tasks increased from 237 minutes to 726 minutes when their child became unwell.  
Interestingly, 726 minutes converts exactly to twelve hours – the time taken to give an overnight feed 
via gastrostomy.  There are many reasons for outliers, most often related to a form of error, however in 
this case the outlier is most likely to be a legitimate case taken from the correct population; with the 
parent feeling they were engaged in the treatment task for the full twelve hours; possibly due to 
monitoring their child throughout, or disturbed sleep etc.  In the case of legitimate outliers, opinion 
varies on how to deal with it, with some authors advocating removal, others the use of transformation 
and others inaction (146).  As this is most likely to be a legitimate outlier, removal seemed 
inappropriate; as such the data were analysed both with the outlier included, and with it truncated to 
reflect the same time difference as the next highest value.  When both sets of data were analysed there 
was no difference, with both analyses resulting in a p-value of 0.07 (see appendix 3.17). 
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As well as possibly introducing bias into the study, the small sample size has had other effects.  Of 
interest, though not necessarily of importance, is that the vast majority of the data were skewed rather 
than normally distributed, necessitating in some cases the use of non-parametric tests, and in others, 
transformation of the data in order for them to be effectively analysed.  For a distribution to assume 
normality a minimum of thirty observations are required.  This is related to the central limits theorem, 
which states that “the distribution of means of samples taken from any population will tend towards the 
normal distribution as the size of the samples taken increases” (145), which essentially means that if you 
take enough samples the distribution of the means will eventually become normal.  The benefit of using 
non-parametric tests to analyse the data is that these tests tend to be more robust than parametric 
methods, allowing their use even when all their assumptions are not met.  The disadvantage is the lesser 
degree of power non-parametric tests have in comparison to parametric tests, leading to the decision to 
transform the core data relating to the number or minutes per day and the average effort.   
 
No previous work exists on the change in time and effort spent on treatment when a child with CF 
develops a pulmonary exacerbation, and so comparing it directly to the work of others is difficult.  The 
nearest studies conducted are those by Ziaian (98) and Sawicki (118), examining the time spent on 
treatments during periods of stability.  And, even in these cases, comparison is made difficult as both 
use the mean and SD to describe the average treatment times, which is not the case here.  In their study 
of stable paediatric patients with CF, Ziaian et al describe that children spent a mean of 59.6 minutes in 
treatments tasks as reported by their parents (98).  This is somewhat less than the median 105 minutes 
spent on treatment when the child is well reported here; which appears to be more closely related to 
the mean of 108 minutes described in the adult population of Sawicki et al (118).   An explanation for 
this may be sought in the clinical parameters of each of the populations; yet this is not forthcoming, as 
they are not reported by Ziaian at el, and the mean FEV1 of those in the Sawicki study is just 61%; rather 
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different to the mean FEV1 of 92% in this study.  A second explanation could be the differences in the 
methods applied in the collection of the data, with both Ziaian and Sawicki employing telephone 
interview methods, asking for the time taken to complete all treatments in the previous 24 hours 
(98,118). This may be beneficial in that recall bias will be minimised, however, this method also has the 
potential to over or under estimate the time patients generally spend on treatments, as the previous 
day may have been different for some reason to a ‘normal’ day, an event which is not accounted for in 
either methodology.   
 
As such, this study does not correlate with the existing literature on the amount of time treatments take 
to complete for CF patients, and so further work in this area would be useful to clarify this issue.  It is 
promising, however, that the work of Ziaian et al demonstrated that the time spent on treatments 
correlated with disease severity (p≤0.05), which lends some support to the difference in treatment time  
during pulmonary exacerbation shown here (98).    
 
In terms of the caregiving literature, a number of aspects of the caregiver burden concept have been 
upheld by this study.  Firstly, the observation that the majority of caregivers are female (75-77), has 
been supported here as 100% of the caregivers in this study were mothers.  Furthermore, the 
supposition that burden is dynamic and changes over time (88), has been strongly supported by the 
finding that the time spent on treatment tasks by a parent increases during periods of child illness, and 
that this difference in time, correlates with a change in effort required to administer those treatments.  
Finally, the slight increase in BDI score during periods of child illness provides some evidence to support 
the existence of negative consequence as a result of caregiving (105).   
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This demonstrates the relevance of the burden concept to parents of children with CF, and emphasises 
the lack of research conducted to date in the area.  Burden is a complex concept, with multiple facets, 
and without an understanding of its symptoms and impact in CF, little can be done to help those parents 
who do experience burden, and the negative consequence associated with it, as a result of caring for 
their child.    
 
Importantly, this study has demonstrated that the time parents spend on caregiving tasks relates to the 
degree of effort involved in those tasks.  Clinicians should remain aware of this, particularly when adding 
to or altering a child’s treatment regimen.  This is a finding which is not just relevant during periods of 
pulmonary exacerbation, but at any time when changes to treatment are being considered. 
 
The trend for the time spent on treatments to increase during a pulmonary exacerbation was expected; 
particularly given that the number of treatments tend to increase during a pulmonary exacerbation, 
with at minimum, the addition of an oral back-up antibiotic (10).  In more severe exacerbations, or with 
a new growth of P. Aeruginosa, more stringent measures are often taken, such as the commencement 
of nebulised colistin or tobramycin (43) or a course of IV antibiotics either in hospital or at home (44), as 
only one patient in this study was started on a nebuliser, and none on IV antibiotics, further research 
including patients with more severe exacerbations may well demonstrate a difference. 
 
As mentioned previously, the main hindrance presented by the small sample size is the resultant 
inability to confidently draw statistical significance from the results.  However, just because the change 
detected between the well and unwell time points cannot be said to be statistically significant, does not 
mean that that change may not be clinically relevant to children with CF and their parents.  To 
determine whether a change is clinically significant, the minimal clinically important difference (MCID) 
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must be ascertained; it is defined as “the smallest difference in score in the domain of interest which 
patients perceive as beneficial and which would mandate, in the absence of troublesome side effects 
and excessive cost, a change in patients management” (147).  In terms of the CLCF and the difference in 
the number of minutes per day spent on treatment, this would be mean the minimum increase in 
minutes spent on treatments which the parent felt was troublesome, or which made a difference to 
their ordinary routine, which they felt would warrant some kind of intervention.  This could be applied, 
not only during periods of illness, but also in other areas of CF management, such as the introduction of 
new treatments and the increase or decrease in time and effort that change elicited.   
 
Most clinical measures have had their MCID determined through the expertise of the clinicians 
administering them.  That is, through repeated use and seeing large numbers of patients, they are able 
to intuitively determine the variation in score which is meaningful to patients.  This is a valid method for 
determining MCID (147).  However, at this stage, the CLCF, like many other questionnaires, remains a 
research tool, and so the latter approach is not currently practical.   Other methods do exist, namely, 
anchor based methods, which entail asking the patients themselves, or mathematical methods.  As 
MCID is the patient’s perception of an important change, anchor methods are preferred for maintaining 
the subjectivity of the value (148).  This approach was successfully used by Jaeschke et al to determine 
the MCID of the Chronic Respiratory Questionnaire and the Chronic Heart Failure Questionnaire by using 
within-patient health transition global ratings; patients completed the questionnaires and a scale rating 
perceived changes in their functional abilities and emotional functioning.  The MCID determined in this 
way corresponded with the author’s suggestion based upon their clinical experience (147).  Other 
methods do exist, but will not be discussed here (148).  However, of interest, is the suggestion that 
irrespective of the method used, all values “converge in the same neighbourhood” (149), and it has been 
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demonstrated that half the SD of the change is a simple and applicable method of estimating the MCID 
(the ½SD method) (150,151), which may later be tested with more rigorous methods.  
 
 Whether this approach is compatible with skewed data, as in this study, is not discussed, and so its 
relevance is unknown.  For interest, the SD of the within-person difference in minutes per day was 
143.47 minutes, giving a ½SD, of 71.8 minutes.  Taking the median (due to the skewed distribution) of 
the within-person difference in minutes per day of 53 minutes, using this approach, the change would 
not be considered clinically significant.  However, using the mean within-person difference in minutes 
per day of 76 minutes the change is clinically significant.  The suggested MCID of 71.8 minutes cannot be 
accepted, due to the skewed distribution of the CLCF data, and similarly whether or not the change 
detected is clinically significant cannot be determined.  However, it does pose an interesting question, 
and certainly warrants further research. 
 
As such, along with the planned psychometric analysis this study was a part of, additional work with a 
larger study sample to expand upon the work here, and determine the MCID is warranted.  Prior to this 
study, there were no data available upon which to base a sample size calculation.  However, using the 
data from this study, it has been possible to conduct a power calculation for future studies.   Using the 
mean and standard deviation of the within-person difference of the minutes per day variable, a sample 
size of 40 pairs is required to give 90% power (see appendix 3.14). 
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3.6 Conclusion 
 
This has been a useful study which has contributed to the knowledge base regarding parental burden in 
CF, and, in part, demonstrated the responsiveness of the CLCF questionnaire.  There were a number of 
challenges that have impacted on the study, in particular, the poor response rate.  Despite approaching 
a large number of families, only thirteen completed the study.  The reasons for this have been discussed 
in full above, however, despite these challenges, the results are encouraging, and show that the CLCF 
can provide clinically meaningful data.   In particular the finding of a correlation between the time and 
effort involved in treatment tasks, indicating that, in all likelihood, the amount of effort required of 
parents to care for their child increases with growing time commitments.  The direction of the 
correlation will need to be confirmed with further work.      Furthermore, it has demonstrated a trend 
towards an increase in time commitments during periods of pulmonary exacerbation, an important, if 
not statistically significant, finding if taken in conjunction with the correlation between time and effort.  
Finally, a trend may also exist in the prevalence of mood disturbance related to the degree of child 
illness.  
 
If nothing else, this study has also shown that, in this study population at least, parents spend, on 
average, well over one hour a day on treatment tasks for their child just when their child is well.  This is 
a big commitment given that the vast majority of these parents worked full or part time, and had at 
least one other child.  Taking into account the active research field of CF, and the large number of 
potential therapies available, it is clear that this time and effort commitment may only get worse. 
 
There is an urgent need for valid, reliable patient reported outcome measures to determine treatment 
burden, both when assessing these new treatments in clinical trials, and in the real-life setting.  And, 
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with growing knowledge of the time and effort involved in caring for a chronically ill relative, and the 
burden this can create, clinicians will need to learn to be ever more aware, and consider the wider 
impact, of the care-giving role they ask parents to take on, and bear this in mind when making 
treatment decisions. 
 
There is further work to be done on the CLCF, and there are multiple possibilities with regards to this.  
Completing the psychometric analysis and confirming the measure’s validity and reliability are most 
important.  However, beyond that, there are other avenues to explore, from confirming the findings of 
this study to examining whether the use of the measure in the clinical setting improves parent self-
efficacy.   
 
A final, note is required to emphasise the importance of continuing to develop the CF burden knowledge 
base in general, rather than focusing on the use of parent reported outcomes in clinical trials.   As 
increasingly complex health tasks are being transferred into the care of parents, an awareness of the 
problem of treatment burden, and, especially, interventions to tackle it, will become ever more 
important, and so this area of research should not be neglected. 
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Appendix 1.1 
The Schwachman Score 
  
POINTS GENERAL 
ACTIVITY 
PHYSICAL 
EXAMINATION 
  
NUTRITION 
  
X-RAY 
FINDINGS 
  
25 Full normal 
activity. Plays 
ball, goes to 
school regularly. 
No cough, clear 
lungs, normal HR & 
RR, good posture. 
Weight and 
height above 
25th centile, 
Normal stool, 
good muscle 
mass and tone. 
Normal, clear 
lung 
fields.  
  
20 
  
Lacks endurance, 
tires at end of 
day, 
good school 
attendance. 
Rare cough, normal 
HR, minimal 
hyperinflation, 
clear lungs, no 
clubbing. 
Wt and Ht 15-
20th centile, stool 
slightly abnormal, 
fair muscle tone 
and mass. 
Minimal 
accentuation 
of 
bronchovascular 
markings, early 
hyperinflation. 
15 May rest 
voluntarily, tires 
easily after 
exertion, fair 
school 
attendance, tires 
after exertion. 
Occasional 
cough/wheeze, 
increased RR, mild 
hyperinflation, 
early clubbing. 
Wt and Ht above 
3rd centile, stools 
often abnormal, 
large and poorly 
formed, minimal 
abdominal 
distension, 
reduced muscle 
mass and poor 
tone. 
Mild 
hyperinflation, 
patchy 
atelectasis, 
increased 
bronchovascular 
markings. 
  
10 Home teacher, 
dyspnoeic after 
short walk, rests 
frequently. 
  
Frequent cough, 
often productive, 
clubbing, chest 
retraction, 
moderate 
hyperinflation, 
wheezes and 
crackles, moderate 
clubbing. 
Wt and Ht below 
3rd centile, bulky 
Offensive stool, 
mild to moderate 
Abdominal 
distension, flabby 
muscles and 
Reduced mass. 
Moderate 
hyperinflation, 
widespread 
atelectasis and 
areas of infection. 
minimal 
bronchiectasis. 
5 Orthopnoeic, 
stays in 
chair or bed. 
Tachypnoea, 
tachycardia, severe 
coughing spells, 
extensive crackles, 
cyanosis, signs of 
heart failure, 
severe clubbing. 
Marked 
malnutrition 
With protuberant 
Abdomen, rectal 
Prolapse, large 
foul 
Frequent fatty 
stools. 
Severe 
hyperinflation, 
lobar atelectasis 
and 
bronchiectasis, 
nodules / cysts. 
pneumothorax, 
cardiac 
enlargement. 
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Appendix 3.4 
 
Dear Parent or Guardian  
 
Re: Development and validation of a burden of care index for cystic fibrosis  
 
Many people in the healthcare professions are concerned about how much parents are being asked to 
do at home when they have a child with cystic fibrosis. We are inviting you to take part in a piece of 
research that will show how much time and effort goes into caring for a child with cystic fibrosis 
(CF). We would like to enlist your help to validate a measure of treatment burden that we have 
developed so that it can be used in other research studies about CF.  
 
Information pack  
 
You will have received this information pack from Dr Kevin Southern at the CF clinic or one of your 
regular healthcare team members. Please take your time and read it carefully. If you have any 
questions about the study or would like the information explained to you then please let the person 
know who gave you this pack as s/he would be happy to do so.  
 
The information pack includes two leaflets describing the study – one is for you and if your child is 
of an age to understand what we are asking you to do (about 8 or 9 years of age) then the other is for 
him/her. We only need parents to take part not the children but we think that it is sometimes helpful 
for children to know what is happening and why we are speaking to you.  
 
We have enclosed a consent form for you to sign if you agree to take part.  
I can be contacted at Royal Liverpool Children’s Hospital - Alder Hey, in the Academic Child 
Mental Health Unit, Tel: 0151 252 5509 or leave a message on my Voicemail: 020 7631 6694. 
Alternatively you could e-mail me: glassc@liv.ac.uk  
 
Kiri Dyer is a MPhil student who is training as a doctor and is working with me over the next year. 
One or other of us will contact you in a few days after you have had time to think about whether you 
would like to take part to see what you decide.  
Thank you for reading this letter.  
 
 
Yours faithfully  
 
 
Dr Claire Glasscoe,  
Senior Research Fellow – University of Liverpool  
Senior Research Associate – Birkbeck University of London 
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Appendix 3.5 
 
PARENT AND/OR CARER INFORMATION DOCUMENT – CF group  
 
TITLE: The development and validation of a Burden of Care Index for cystic fibrosis  
 
INVESTIGATORS: Dr Claire Glasscoe, Senior Research Fellow Dr Kevin Southern, Reader in 
Respiratory Medicine Miss Kiri Dyer, Medical Research Student  
 
WHAT IS THIS STUDY ABOUT?  
This study aims to develop a measure to estimate the actual burden of care dealt with by families 
with a child with cystic fibrosis on day to day basis. Treatment protocols are often complicated and 
tailored to the individual child. We want this measure to capture the complexity and be sensitive to 
changes over time so we can study the effect on families in the long term.  
 
WHAT WILL IT INVOLVE FOR MY FAMILY AND ME?  
You are being invited to take part in this study because your child has cystic fibrosis and we think 
you can help us to describe the treatment demands. The study will involve only you as parents; no 
one else in your family will be seen. You will be asked to complete questionnaires at two time points 
when you think there has been a change for better or worse in your child’s health. This could be a 
respiratory infection that needs antibiotics or recovery from an infection. One of these questionnaires 
is the measure we a trying to develop and the others relate to your mood and your child’s quality of 
life. The schedule for completion of the questionnaires is as follows:  
 
Time 1 – the start of the study – 4 questionnaires  
 
Time 2 – when you think there has been a change in your child’s health – 4 questionnaires  
 
If you were willing you may also be asked to take part in two face to face interviews to describe how 
your child’s treatment changes from day-to-day and how well you think the measure reflects those 
changes.  
 
HOW TIME CONSUMING IS THIS GOING TO BE?  
We appreciate this can be a busy and difficult time for you as parents and every effort will be made 
to fit with your commitments. Questionnaires take about 10-20 minutes each to complete totalling 
approximately 100 minutes over the study period. They can be filled in at the clinic or at home 
whichever you prefer. We will give you a reply paid envelope for any you do at home. If you are 
asked to take part in the interviews then this could take place during a hospital visit or at your home 
at a time that suits you and would take about one and a half hours each. Version 4a, sensitivity15/08/2008  
 
WILL THE INFORMATION BE KEPT PRIVATE? 
 All the information you give will be kept confidential. Your family will be allocated a code number 
and no identifying material will be available to any one, not even your child's doctor. The only 
situation where confidentiality cannot be kept would be if someone were at risk of harm or serious 
mental illness in which case the interviewer would discuss with you how this should be managed.  
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CAN I CHANGE MY MIND AFTER I HAVE SIGNED THE CONSENT FORM?  
You are under no obligation what so ever to take part in this study - it is purely a voluntary 
agreement. You can change your mind at any time throughout the process and this would in no way 
affect your child's treatment.  
 
WHAT ARE THE BENEFITS OF THIS RESEARCH?  
There is no direct benefit to you or your child from taking part in this study. However, the 
opportunity to review what treatments you are doing or talk about how you are managing can 
sometimes be help in itself. If any part of the study raises questions for you that you would like to 
discuss in more depth then please let us know as Kiri Dyer or Claire Glasscoe would be happy to 
discuss them with you and ensure you had quick access to the most appropriate service for your 
needs.  
 
ARE THERE ANY RISKS INVOLVED?  
There are no risks as such although some parents may not want to talk about what is happening or 
feel that filling out questionnaires is an added burden they could do without at this point in time.  
 
CAN WE DISCUSS THIS FURTHER BEFORE COMMITTING OURSELVES?  
Yes, Claire Glasscoe would be happy to discuss any questions you have, she is contactable in 
Mulberry House at Royal Liverpool Children’s Hospital – Alder Hey in the Child Mental Health 
Unit, Tel: 0151 252 5509 or you can leave a message on her Voicemail: 020 7631 6694. Dr Kevin 
Southern is at Alder Hey Children’s Hospital would also be happy to discuss any questions you have 
about the study and he can be contacted by email (kwsouth@liv.ac.uk).  
WHAT WILL HAPPEN TO THE RESULTS OF THE STUDY?  
The study will be published in scientific journals and you will have the option of receiving a 
summary of the findings when they are published. In addition we will be constructing a website that 
you will be able to access securely for regular news bulletins about the study 
WHAT HAPPENS NOW?  
You will be contacted in one week’s time by Claire Glasscoe or Holly Hope, Research Assistant after 
you have had time to think and if you decide to take part in the study then you will be asked to sign a 
consent form at you next clinic visit. After that you will receive the questionnaires for completion 
either in the clinic or once you return home in which case we would give you a reply paid envelope 
for their return. 
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PATIENT INFORMATION DOCUMENT 
 
TITLE:     The development and validation of a Burden of Care Index for cystic fibrosis 
 
INVESTIGATORS:   Dr Claire Glasscoe  
                                     Dr Kevin Southern 
                                     Miss Kiri Dyer 
 
Medical discoveries mean that treatments for children with cystic fibrosis are improving all the 
time. There are a lot of treatments for cystic fibrosis that can be hard to describe or take up a 
good deal of time to do. The following are some questions you might have: 
 
WHAT IS IT ABOUT: We want to understand how parents manage the treatments for cystic 
fibrosis. To do this we are asking your parents to take part in a study that will develop a measure 
to describe the types of treatment you have to take, how complicated they are and how easily 
they can be done so as not to interfere with how you live your life.  
 
WHAT WILL IT INVOLVE FOR MY FAMILY AND ME: Your parents are being invited to 
take part in this study because you have cystic fibrosis and we think they can help us to describe 
the demands made by the treatments for CF. The study will not involve you only your parents 
and no one else in your family will be seen. They will be asked to fill out some questionnaires 
and maybe to come to a meeting with other parents to help us to find the best questions for our 
measure. 
 
HOW LONG WILL THIS TAKE: We know that family life is often busy with many things to 
do. We will take up as little of your parents’ time as possible. 
 
WILL THE INFORMATION BE KEPT PRIVATE: All the information your parents give 
will be kept private. The only time we cannot be keep things private is when we hear about 
someone being at risk of harm in which case we would discuss with your parents how this might 
best be sorted out. 
 
CAN I CHANGE MY MIND AFTER I HAVE SIGNED AN ASSENT FORM: You do not 
need to agree to your parents taking part in this study. If you do not want them to talk to us or to 
help us to construct this measure then you have every right to say NO. If you do agree then you 
can change your mind at any time and this would not affect the treatment you get from the 
doctors.  
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HOW MIGHT WE STAND TO GAIN: This measure won’t help you directly. However, some 
parents may be glad of the opportunity to review what treatments you are doing or talk about 
how they are managing with other parents or in private. If at any time you or your parents have 
any questions about further help that may be available then Claire Glasscoe or Kiri Dyer would 
be happy to discuss them with you and your parents.    
 
ARE THERE ANY RISKS INVOLVED: There are no risks as such although some families 
may prefer not to talk about what is happening or feel that filling out questionnaires is an added 
burden they could do without at this point in time. 
 
CAN I TALK ABOUT THIS WITH SOMEONE BEFORE AGREEING: Yes, Claire 
Glasscoe or Kiri Dyer would be happy to talk with you about any questions you have, they are 
based in Alder Hey in Mulberry House, Tel: 0151 252 5509 or you can leave a message on 
Claire Glasscoe’s Voicemail: 020 7631 6694 
 
HOW WILL I KNOW WHAT THE RESULTS ARE: The study will be published in 
scientific journals. Your parents will have the option of receiving a summary of the results when 
they are published and we will include a leaflet about what we found for the children whose 
parents were involved. We will also be constructing a website that your parents will be able to 
visit securely for regular news about how the study is going. 
 
WHAT HAPPENS NOW: Your parents will be contacted in one week’s time by Claire 
Glasscoe or Kiri Dyer after you have all had time to think and if your parents decide they would 
like to take part in the study then you may be asked to sign an assent form at your next visit to 
the hospital. Your parents will receive the questionnaires for completion either in the clinic or 
once you return home.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
123 
 
Action 
Research 
Appendix 3.7 
 
 
124 
 
Action 
Research 
Appendix 3.8 
 
RESEARCH ASSENT FORM for children aged about 8 years and older 
 
Title of study:  
 
Development and Validation of a Burden of Care Index (BoCI) for cystic fibrosis 
 
Names of Investigators…Dr Claire Glasscoe………………………………………………………… 
……………………………Dr Kevin Southern………………………………………………………… 
……………………………Miss Kiri Dyer………………………………………………………………... 
………………………………………………………………………………………………………………. 
 
            
o I confirm that the above study has been fully explained to me       
 
 
o I was given an opportunity to hear more about the study  
by one of the investigators   
 
 
o I was given a copy of the patient information document     
 
 
o I was given information about how to find out about the results  
      of this study            
 
 
 
Participation in this study is entirely voluntary. Your parents can withdraw from the study without 
giving a reason and in the knowledge that withdrawal will not affect the treatment you receive 
from the doctors. 
 
 
I …………………………………….give my permission to be included in the above titled study  
       (please print your name) 
 
 
Signature  ………………………………………………………………………………………………….. 
 
Top copy- to be retained in Medical Case notes.  
Yellow copy- to be retained by parent/person with parental responsibility. 
Green copy- to be retained by the investigator 
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Dear Parent or Guardian 
 
Re: Development and validation of a burden of care index for cystic fibrosis 
 
You are receiving this letter because at a recent clinic visit you were approached by me regarding a 
research project based at Alder Hey Children’s Hospital looking at the time and effort that goes into 
caring for a child with Cystic Fibrosis (CF), and testing a new questionnaire that has been developed by 
the CF team. 
I would like to thank you for taking the time to return the first set of questionnaires and remind you that 
we also need to receive the second set of questionnaires in order to compare your responses at the two 
time points in order to test the questionnaire. 
You have already completed the questionnaires at the “well” time point, and I would like to take the 
opportunity to clarify what is meant the “unwell” time point: 
Unwell – a time when your child is on their backup antibiotics due to two or more of: 
1. Increased cough 
2. Increased sputum 
3. Shortness of breath 
4. Weight loss 
5. A doctor hearing wheeze or crackles in their chest 
6. Days off school 
 
I would greatly appreciate it if you could fill out the second set of questionnaires at the next appropriate 
opportunity, and have included them with this letter  
 
If you have any questions regarding any aspect of the study or have decided not to continue to take part 
please contact me at K.L.Dyer@student.liverpool.ac.uk or  07983602755. 
 
Many Thanks 
Kiri Dyer 
 
MPhil Student, Alder Hey Children’s Hospital CF Unit & University of Liverpool 
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Bonferroni correction for parent characteristics 
 
If no correction would be applied you would 
have a chance of 0.7226 (72.26%) of finding one or 
more significant differences in 25 tests. 
 
  ** Adjustments without correlation ** 
  ** To get an alpha level overall of 0.05 ** 
 
Sidak's adjustment 
Lower the alpha for each test to 0.002049628 
z-value for single sided testing: >=2.8704 
z-value for double sided testing: >=3.0829 
 
Bonferroni's adjustment 
Lower the alpha for each test to 0.002 
z-value for single sided testing: >=2.8782 
z-value for double sided testing: >=3.0902 
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Bonferroni correction child characteristics 
 
If no correction would be applied you would 
have a chance of 0.6226 (62.26%) of finding one or 
more significant differences in 19 tests. 
 
  ** Adjustments without correlation ** 
  ** To get an alpha level overall of 0.05 ** 
 
Sidak's adjustment 
Lower the alpha for each test to 0.002696006 
z-value for single sided testing: >=2.7826 
z-value for double sided testing: >=3.0004 
 
Bonferroni's adjustment 
Lower the alpha for each test to 0.002631579 
z-value for single sided testing: >=2.7905 
z-value for double sided testing: >=3.0078 
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Correlations 
   MinsDiff EffortDiff BDIdiff STAI_Y1diff STAI_Y2diff 
Spearman's rho MinsDiff Correlation Coefficient 1.000 .621
*
 .254 .525 .262 
Sig. (2-tailed) . .024 .425 .079 .464 
N 13 13 12 12 10 
EffortDiff Correlation Coefficient .621
*
 1.000 .201 .259 .232 
Sig. (2-tailed) .024 . .530 .416 .519 
N 13 13 12 12 10 
BDIdiff Correlation Coefficient .254 .201 1.000 .437 .163 
Sig. (2-tailed) .425 .530 . .155 .653 
N 12 12 12 12 10 
STAI_Y1diff Correlation Coefficient .525 .259 .437 1.000 .590 
Sig. (2-tailed) .079 .416 .155 . .072 
N 12 12 12 12 10 
STAI_Y2diff Correlation Coefficient .262 .232 .163 .590 1.000 
Sig. (2-tailed) .464 .519 .653 .072 . 
N 10 10 10 10 10 
*. Correlation is significant at the 0.05 level (2-tailed). 
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Outlier Analysis 
 
Output with outlier included 
 
 
Paired Samples Test 
  Paired Differences 
t df 
Sig. (2-
tailed) 
  
Mean 
Std. 
Deviation 
Std. Error 
Mean 
95% Confidence 
Interval of the 
Difference 
  Lower Upper 
Pair 
1 
NormMinsperDay_well - 
NormMinsperDay_unwell 
-
2.77997 
4.95886 1.37534 -5.77658 .21664 -2.021 12 .066 
 
 
 
Output with outlier truncated 
 
 
 
Paired Samples Test 
  Paired Differences 
t df 
Sig. (2-
tailed) 
  
Mean 
Std. 
Deviation 
Std. Error 
Mean 
95% Confidence 
Interval of the 
Difference 
  Lower Upper 
Pair 
1 
NormMinsperDay_well - 
NormMinsperDay_unwell 
-
2.47228 
4.46930 1.23956 -5.17305 .22849 -1.994 12 .069 
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Sample size for a paired or single sample Student t test   
 
Alpha = 0.05 
Power = 0.9 
Difference of mean from zero = 76* 
Standard deviation = 143.47* 
 
Estimated minimum sample size = 40 pairs 
 
Degrees of freedom = 39 
 
 
Statistics 
Minutes Difference 
N Valid 13 
Missing 0 
Mean* 76.0000 
Std. Deviation* 143.37015 
 
 
